var title_f7_15_7408="Fibrin plug eso varix Endosc";
var content_f7_15_7408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Fibrin plug on an esophageal varix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Upper endoscopy reveals two chains of varices (9 and 5 o'clock). A yellowish fibrin plug is visible in the 9 o'clock varix indicating the site of recent bleeding. Right panel: Close-up view of the fibrin plug.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7408=[""].join("\n");
var outline_f7_15_7408=null;
var title_f7_15_7409="Rimonabant: International drug information";
var content_f7_15_7409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rimonabant: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4292220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acomplia (AT, BE, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, NL, NO, PL, PT, SE, SI)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4299047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Endocannabinoid CB1 Receptor Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4292221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct treatment to diet and exercise for obese patients (body mass index &gt;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) or overweight patients (body mass index &gt;27 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) with associated risk factor(s) such as type 2 diabetes mellitus (noninsulin dependent, NIDDM) or dyslipidemia",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4292223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents &ge;18 years and Adults: Oral: 20 mg/day before breakfast",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4292224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10523 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7409=[""].join("\n");
var outline_f7_15_7409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4292220\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4299047\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4292221\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4292223\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821146\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4292224\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10523\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10523|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_15_7410="Treatment protocols for soft tissue and bone sarcoma";
var content_f7_15_7410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for soft tissue and bone sarcoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7410/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7410/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7410/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7410/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7410/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7410/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7410/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/15/7410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8525761\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of adult patients with soft tissue and bone sarcomas.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with sarcomas. Additional regimens may be added over time, particularly as treatment for bone and soft tissue sarcoma evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with sarcomas. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link\">",
"       \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link\">",
"       \"Systemic treatment of metastatic soft tissue sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link\">",
"       \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=see_link\">",
"       \"Chemotherapy and radiation therapy in the management of osteosarcoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8525768\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85120418\">",
"    <span class=\"h2\">",
"     Bone sarcomas",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H825943302\">",
"    <span class=\"h3\">",
"     Doxorubicin plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef87182 \" href=\"UTD.htm?34/6/34926\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H463344128\">",
"    <span class=\"h3\">",
"     Methotrexate plus doxorubicin and cisplatin (MAP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef87346 \" href=\"UTD.htm?20/20/20800\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85120378\">",
"    <span class=\"h2\">",
"     Soft tissue sarcomas",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936759827\">",
"    <span class=\"h3\">",
"     Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 60/6)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56240 \" href=\"UTD.htm?37/54/38766\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936759852\">",
"    <span class=\"h3\">",
"     Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 75/9)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67985 \" href=\"UTD.htm?40/20/41294\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936759877\">",
"    <span class=\"h3\">",
"     Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 75/10)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef81370 \" href=\"UTD.htm?2/42/2735\">",
"     table 5",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936759902\">",
"    <span class=\"h3\">",
"     Gemcitabine plus docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef58713 \" href=\"UTD.htm?25/6/25710\">",
"     table 6",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7613292\">",
"    <span class=\"h3\">",
"     Pegylated liposomal doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef88268 \" href=\"UTD.htm?24/16/24846\">",
"     table 7",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85692 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-1B4384F6EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7410=[""].join("\n");
var outline_f7_15_7410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8525761\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8525768\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85120418\">",
"      Bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H825943302\">",
"      - Doxorubicin plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H463344128\">",
"      - Methotrexate plus doxorubicin and cisplatin (MAP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85120378\">",
"      Soft tissue sarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H936759827\">",
"      - Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 60/6)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H936759852\">",
"      - Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 75/9)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H936759877\">",
"      - Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 75/10)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H936759902\">",
"      - Gemcitabine plus docetaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7613292\">",
"      - Pegylated liposomal doxorubicin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85692\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85692|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/6/34926\" title=\"table 1\">",
"      Doxorubin plus cisplatin osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/20/20800\" title=\"table 2\">",
"      MAP osteosarcoma young adults and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/54/38766\" title=\"table 3\">",
"      AIM 60_6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/20/41294\" title=\"table 4\">",
"      AIM 75_9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/42/2735\" title=\"table 5\">",
"      AIM 75_10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/6/25710\" title=\"table 6\">",
"      Gem plus doc for advanced sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/16/24846\" title=\"table 7\">",
"      PLD for soft tissue sarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=related_link\">",
"      Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=related_link\">",
"      Chemotherapy and radiation therapy in the management of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=related_link\">",
"      Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_15_7411="Bepotastine: Drug information";
var content_f7_15_7411=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bepotastine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/8/128?source=see_link\">",
"    see \"Bepotastine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8119768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bepreve&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8769130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Mast Cell Stabilizer",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9412509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Ophthalmic:  Instill 1 drop into the affected eye(s) twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9412508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Ophthalmic: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9412510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9412513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as besilate [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bepreve&reg;: 1.5% (5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9412445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9412511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only. Contact lenses should be removed prior to application, may be inserted after 10 minutes. Do not insert contacts if eyes are red. Avoid contaminating the applicator tip.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8769131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of itching associated with allergic conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9412454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Gastrointestinal: Taste abnormality (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Irritation (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Hypersensitivity reactions, itching, rash, swelling of lips/throat/tongue",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9412450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bepotastine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9412451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 10 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For topical ophthalmic use only. Not for the treatment of contact lens irritation; do not wear contact lenses if eye is red.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9518196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9412446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9412447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in most animal reproduction studies following oral administration; however, a decrease in fetal weight and a decrease in live births were observed in some studies. In humans, plasma concentrations are below the limit of quantification (&lt;2 ng/mL) 24 hours after ophthalmic administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9412449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bepreve Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5% (5 mL): $152.84",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Talion (ID, JP, KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9412459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Direct H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist and inhibits release of histamine from mast cells",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9412461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 3 minutes (Macejko, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Up to 16 hours (Williams, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Minimal systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Minimal via CYP enzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~75% to 90% unchanged)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abelson MB, Torkildsen GL, Williams JI, et al, \"Time to Onset and Duration of Action of the Antihistamine Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% in Allergic Conjunctivitis: A Phase III, Single-Center, Prospective, Randomized, Double-Masked, Placebo-Controlled, Conjunctival Allergen Challenge Assessment In Adults and Children,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2009, 31(9):1908-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/15/7411/abstract-text/19843481/pubmed\" id=\"19843481\" target=\"_blank\">",
"        19843481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Macejko TT, Bergmann MT, Williams JI, et al, \"Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis,\"",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 2010, 150(1):122-127.e5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/15/7411/abstract-text/20488431/pubmed\" id=\"20488431\" target=\"_blank\">",
"        20488431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams JI, Kennedy KS, Gow JA, et al, \"Prolonged Effectiveness of Bepotastine Besilate Ophthalmic Solution for the Treatment of Ocular Symptoms of Allergic Conjunctivitis,\"",
"      <i>",
"       J Ocul Pharmacol Ther",
"      </i>",
"      , 2011, 27(4):385-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/15/7411/abstract-text/21649522/pubmed\" id=\"21649522\" target=\"_blank\">",
"        21649522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8819 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7411=[""].join("\n");
var outline_f7_15_7411=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119768\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8769130\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412509\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412508\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412510\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412513\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412445\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412511\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8769131\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412454\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412450\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412451\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298851\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518196\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412446\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412447\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412449\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322700\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276707\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412459\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9412461\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8819|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/8/128?source=related_link\">",
"      Bepotastine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_15_7412="Rigid bronchoscopy: Intubation techniques";
var content_f7_15_7412=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rigid bronchoscopy: Intubation techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7412/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7412/contributors\">",
"     Henri G Colt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7412/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7412/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7412/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7412/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/15/7412/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rigid bronchoscope, which is a hollow stainless steel tube through which a rigid telescope is placed, provides access to the central airways. External diameters and lengths vary depending upon the manufacturer. The distal end of the rigid bronchoscope is usually beveled to facilitate intubation and lifting of the epiglottis; the proximal portion is equipped to accommodate attachments, provide side port ventilation, and permit insertion of ancillary instruments.",
"   </p>",
"   <p>",
"    Intubation with the rigid bronchoscope usually prompts the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What anesthesia and patient preparation techniques are commonly used?",
"     </li>",
"     <li>",
"      How is direct intubation performed?",
"     </li>",
"     <li>",
"      Is laryngoscopically-guided intubation possible?",
"     </li>",
"     <li>",
"      Can intubation be performed through a tracheostomy?",
"     </li>",
"     <li>",
"      What complications arise from faulty technique?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues relating to the general procedures surrounding the intubation techniques of rigid bronchoscopy will be reviewed here. The history of rigid bronchoscopy (including current instrumentation) and an overview of bronchoscopy (including indications and contraindications) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37394?source=see_link\">",
"     \"Rigid bronchoscopy: Instrumentation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general preparative procedures should be performed prior to intubation using a rigid bronchoscope (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical anesthesia is applied using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36032?source=see_link\">",
"       tetracaine",
"      </a>",
"      . Additional topical anesthetic is usually administered to the tracheobronchial tree after intubation with the rigid bronchoscope.",
"     </li>",
"     <li>",
"      Patients are oxygenated by mask, and pharyngeal secretions are aspirated.",
"     </li>",
"     <li>",
"      Dentures are removed, and the teeth and gums are carefully inspected. The teeth may be protected with gauze pads, foam rubber, or plastic mouth guards.",
"     </li>",
"     <li>",
"      Some operators place a rolled blanket or towel between the shoulder blades in order to thrust the upper trachea forward and extend the cervical spine. Others suspend the head and neck over the edge of the operating table and support them with the bronchoscopist's knee.",
"     </li>",
"     <li>",
"      Depending upon the position of the glottis and the laryngotracheobronchial axis, it may be necessary to use one, two, or no pillows beneath the patient's head when it is resting on the table. Careful attention should be paid to patients with cervical spine disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anesthesiologists have become increasingly comfortable with intravenous general anesthesia, which avoids the administration of potentially noxious gases. Muscle relaxation and paralysis can be avoided with the use of assisted spontaneous ventilation, and wake-up time may be shortened. The combination of intravenous general anesthesia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and assisted spontaneous ventilation is currently the most frequently used anesthesia technique for rigid bronchoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7412/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete muscle relaxation is occasionally desirable, particularly if rigid bronchoscopy is stimulating and if work is being performed within the lower airways. When general anesthesia with inhaled gases is employed, it is essential to pack the nose and mouth to avoid gas leakage (",
"    <a class=\"graphic graphic_picture graphicRef68727 \" href=\"UTD.htm?22/8/22671\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7412/abstract/2\">",
"     2",
"    </a>",
"    ]. Packing, however, may impede manipulation of the rigid bronchoscope within the tracheobronchial tree. When packing is performed, Vaseline gauze is used in the nasal passages, and rolled gauze is placed in the mouth, firmly securing the rigid bronchoscope.",
"   </p>",
"   <p>",
"    Ventilatory support can be provided using assisted spontaneous ventilation or closed-circuit positive pressure ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7412/abstract/1\">",
"     1",
"    </a>",
"    ]. High frequency ventilation is favored by some experts, but availability of this modality may be limited [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7412/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H22#H22\">",
"     \"Modes of mechanical ventilation\", section on 'High frequency ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIRECT INTUBATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct intubation using a rigid telescope is the method of choice for rigid bronchoscopic intubation. With this technique, the rigid telescope is placed inside the bronchoscope, and the laryngeal structures are viewed directly through the telescope. Illumination is provided through the distal aspect of the rigid telescope, which is attached via a light cable to a cold light source. By comparison, if a rigid telescope is not used, the bronchoscope is introduced using only the naked eye. The following is a brief summary of the sequential steps required for direct intubation using a rigid telescope:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bronchoscopist stands directly behind the head of the supine patient.",
"     </li>",
"     <li>",
"      The rigid bronchoscope is held in the right hand with its tip uppermost. The middle finger of the left hand is used to protect the upper teeth and gums and to control head movements. The telescope should not extend beyond the edge of the rigid bronchoscope.",
"     </li>",
"     <li>",
"      The bronchoscope is inserted with its tip facing forward. Looking through the telescope, the bronchoscopist identifies the uvula posteriorly, and the bronchoscope is advanced along the route of the tongue.",
"     </li>",
"     <li>",
"      The rigid bronchoscope is gently lifted upwards and the epiglottis is brought into view (",
"      <a class=\"graphic graphic_movie graphicRef71905 \" href=\"UTD.htm?10/32/10766\">",
"       movie 1",
"      </a>",
"      ). The anterior aspect of the beveled tip of the bronchoscope is then slid under the epiglottis. Gentle advancement of the rigid tube provides further access to the larynx.",
"     </li>",
"     <li>",
"      After both arytenoids are identified, the rigid tube is lifted more anteriorly and the vocal cords are seen. As the vocal cords are approached, the tip of the bronchoscope is rotated 90 degrees laterally so that the beveled tip lies between them.",
"     </li>",
"     <li>",
"      The bronchoscope is advanced and rotated to enter the trachea without traumatizing the larynx.",
"     </li>",
"     <li>",
"      Once beyond the level of the cricoid cartilage, the bronchoscope may be rotated so that the beveled tip lies along the posterior wall of the trachea (",
"      <a class=\"graphic graphic_movie graphicRef51963 \" href=\"UTD.htm?36/40/37517\">",
"       movie 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INTUBATION WITH LARYNGOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For operators who are uncomfortable with direct intubation but who are adept at laryngoscopy, the vocal cords may be visualized using the rigid laryngoscope alone. Either straight or curved instruments may be used with intubation during rigid laryngoscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the laryngoscope in the midline and after the epiglottis has been lifted, the rigid bronchoscope is inserted into the lateral aspect of the mouth and directed toward the larynx. Care must be taken to avoid obstruction of the larynx by the rigid tube.",
"     </li>",
"     <li>",
"      As the bronchoscope is inserted between the vocal cords, it is rotated slightly and kept in the midline to avoid striking the beveled edge of the bronchoscope against the lateral wall of the subglottis.",
"     </li>",
"     <li>",
"      Once the bronchoscope is inserted through the cords, the laryngoscope is removed, and the rigid telescope can be placed into the rigid bronchoscope. The bronchoscope is then advanced further into the tracheal lumen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INTUBATION VIA TRACHEOSTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intubation through a tracheostomy is a relatively simple technique. After topical anesthesia with viscous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    applied to the edges of the tracheostomy, the rigid bronchoscope can be inserted directly through the stoma from a lateral position.",
"   </p>",
"   <p>",
"    Tracheostomy intubation is easiest if the bronchoscopist stands behind the patient and slightly to the patient's left or right. Care is taken to insert a long, rigid tube obliquely in order to avoid striking the beveled edge of the rigid bronchoscope against the posterior wall of the trachea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expertise in rigid bronchoscopy requires a long apprenticeship. In addition, bronchoscopists must never forget that they share the airway with the anesthesiologist. Oxygenation and ventilation must always take priority over any manipulations of the rigid bronchoscope.",
"   </p>",
"   <p>",
"    Most complications of rigid bronchoscopy are related to poor insertion technique, prolonged trauma of the larynx and vocal cords, hypercapnia, hypoxemia, or hemodynamic instability. Specific complications include damage to structures of the mouth and oropharynx, laryngeal swelling, spinal cord injury, and airway perforation and injury to the vocal cords and arytenoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Damage to structures of the mouth and oropharynx",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful inspection of the mouth and teeth is essential to avoid dislodging a loose tooth. In addition, the gums should not be traumatized, and the lips should not be injured by accidentally pulling them into the mouth above or below the rigid bronchoscope. Precautions should also be taken in patients who may have herpes infections of the oropharyngeal airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laryngeal swelling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal swelling may occur during or immediately following rigid bronchoscopy. It is unclear, however, whether either inhalation of beta agonists prior to procedure or the administration of intravenous corticosteroids before and after rigid bronchoscopy may be beneficial in preventing this problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Spinal cord injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord injuries are possible in patients with cervical spine disease and severe osteoporosis. In selected cases, the presence of either of these diseases is a contraindication to rigid bronchoscopic intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Airway perforation and injury to the vocal cords and arytenoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major complications that must be avoided are airway wall perforation (particularly of the posterior wall of the trachea and the subglottic region) and luxation or laceration at the level of the vocal cords and arytenoids. Such injuries may occur because of faulty intubation technique or if intubation is attempted before a patient is fully asleep or sufficiently anesthetized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rigid bronchoscope is a potentially dangerous instrument. It consists of a hollow stainless steel tube that provides access to the central airways and through which a rigid telescope is placed. External diameters and lengths vary depending upon the manufacturer. The distal end of the rigid bronchoscope is usually beveled to facilitate intubation and lifting of the epiglottis, while the proximal portion is equipped to accommodate attachments, provide side port ventilation, and permit insertion of ancillary instruments. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The technique of rigid bronchoscopic intubation is one that is gradually perfected over time. Direct intubation using a rigid telescope is the method of choice for rigid bronchoscopic intubation. With this technique, the rigid telescope is placed inside the bronchoscope, and the laryngeal structures are viewed directly through the telescope. For operators who are uncomfortable with direct intubation but who are adept at laryngoscopy, the vocal cords may be visualized using the rigid laryngoscope alone. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Direct intubation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Intubation with laryngoscopy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The bronchoscope can and should be introduced gently, delicately, and with substantial care. Most complications of rigid bronchoscopy are related to poor insertion technique, prolonged trauma of the larynx and vocal cords, hypercapnia, hypoxemia, or hemodynamic instability. Specific complications include damage to structures of the mouth and oropharynx, laryngeal swelling, spinal cord injury, and airway perforation and injury to the vocal cords and arytenoids. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7412/abstract/1\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7412/abstract/2\">",
"      Conacher ID. Anaesthesia and tracheobronchial stenting for central airway obstruction in adults. Br J Anaesth 2003; 90:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7412/abstract/3\">",
"      Perrin G, Colt HG, Martin C, et al. Safety of interventional rigid bronchoscopy using intravenous anesthesia and spontaneous assisted ventilation. A prospective study. Chest 1992; 102:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7412/abstract/4\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7412/abstract/5\">",
"      Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central airway obstruction. Am J Respir Crit Care Med 2004; 169:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7412/abstract/6\">",
"      Natalini G, Cavaliere S, Seramondi V, et al. Negative pressure ventilation vs external high-frequency oscillation during rigid bronchoscopy. A controlled randomized trial. Chest 2000; 118:18.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4391 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-192C8F5B95-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7412=[""].join("\n");
var outline_f7_15_7412=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIRECT INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INTUBATION WITH LARYNGOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INTUBATION VIA TRACHEOSTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Damage to structures of the mouth and oropharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laryngeal swelling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Airway perforation and injury to the vocal cords and arytenoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4391\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4391|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/8/22671\" title=\"picture 1\">",
"      Intubation with rigid bronch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4391|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/32/10766\" title=\"movie 1\">",
"      View through a rigid bronchoscope - mouth to epiglottis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?36/40/37517\" title=\"movie 2\">",
"      View through a rigid bronchoscope - epiglottis to trachea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=related_link\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37394?source=related_link\">",
"      Rigid bronchoscopy: Instrumentation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_15_7413="Removal scutum";
var content_f7_15_7413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Removal of the scutum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When a cholesteatoma has extended beyond the accessible confines of the middle ear, it is necessary to remove cranial bone to reach the temporal bone spaces above and behind the middle ear. In the above figure, the scutum&nbsp;(the thin bony plate separating the upper part of the middle ear from the mastoid cells)&nbsp;has been drilled away to expose the cholesteatoma in the space just superior to the middle ear (ie, the attic or epitympanum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7413=[""].join("\n");
var outline_f7_15_7413=null;
var title_f7_15_7414="Orexin neurons CNS";
var content_f7_15_7414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Orexin neurons in the lateral hypothalamus innervate and excite many wake-promoting brain regions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Targets of the orexin-producing neurons include monoaminergic areas such as the locus coeruleus, raphe nuclei, ventral tegmental area, periaqueductal grey, and tuberomammillary nucleus as well as cholinergic areas such as the basal forebrain and pedunculopontine and laterodorsal tegmental nuclei (PPT/LDT). Increased activity in these monoaminergic areas promotes wakefulness, inhibits REM sleep, and suppresses REM sleep-related phenomena including cataplexy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7414=[""].join("\n");
var outline_f7_15_7414=null;
var title_f7_15_7415="Complications of gynecologic laparoscopic surgery";
var content_f7_15_7415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of gynecologic laparoscopic surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7415/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7415/contributors\">",
"     Thomas G Stovall, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7415/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7415/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7415/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7415/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7415/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/15/7415/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications related to laparoscopy in gynecologic patients are not uncommon. A review including over 1.5 million gynecologic patients reported complications in 0.1 to 10 percent of procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/1\">",
"     1",
"    </a>",
"    ]. Over 50 percent of these complications occurred at entry, and 20 to 25 percent of complications were not recognized until the postoperative period.",
"   </p>",
"   <p>",
"    The following findings were noted in several large studies :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One survey reported results of claims arising from entry access injuries between 1980 and 1999 and entry-injury medical device reports to the FDA [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/2\">",
"       2",
"      </a>",
"      ]. The incidence of entry access injury was 5 to 30 per 10,000 procedures. Bowel and retroperitoneal vascular injuries comprised 76 percent of all injuries and almost 50 percent of small and large bowel injuries were unrecognized for at least 24 hours. The type and proportion of organ injury during entry was: small bowel (25 percent), iliac artery (19 percent), colon (12 percent), iliac or other retroperitoneal vein (9 percent), secondary branches of a mesenteric vessel (7 percent), aorta (6 percent), inferior vena cava (4 percent), abdominal wall vessels (4 percent), bladder (3 percent), liver (2 percent), other (less than 2 percent).",
"     </li>",
"     <li>",
"      A literature review of procedures performed from 1975 to 2002 reported entry-related visceral lesions occurred in 0.3 to 1.3 per 1000 procedures and entry-related vascular lesions occurred in 0.07 to 4.7 per 1000 procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/3\">",
"       3",
"      </a>",
"      ]. The open technique was not associated with fewer complications than the closed technique; however, this result likely reflects the high risk status of patients undergoing the open procedure.",
"     </li>",
"     <li>",
"      An analysis of 629 trocar injuries reported to the FDA included 408 injuries of major blood vessels, 182 other visceral injuries (mainly bowel injuries), and 30 abdominal wall hematomas [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/4\">",
"       4",
"      </a>",
"      ]. Of the 32 deaths, 26 resulted from vascular injuries and 6 resulted from bowel injuries. The aorta and inferior vena cava were the vessels most commonly traumatized in the fatal vascular injuries. The diagnosis of an enterotomy was delayed in 10 percent of cases, and the mortality rate in this group was 21 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications related to gynecologic laparoscopic surgery will be discussed here. Other issues of laparoscopic surgery, including instrumentation and surgical technique, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedures on patients who have had prior surgeries or intraabdominal disease (endometriosis, pelvic inflammatory disease) are associated with a higher risk of complications than simple procedures in women without this past history. Conditions that increase the risk of complications include extensive bowel distention, very large pelvic or abdominal masses, extensive",
"    <span class=\"nowrap\">",
"     pelvic/intraabdominal",
"    </span>",
"    adhesions, cardiopulmonary disease, and diaphragmatic hernia. Patients with these conditions are often better served with a nonlaparoscopic surgical approach.",
"   </p>",
"   <p>",
"    As with other surgical procedures, the number of complications appears to be related to the surgeon's experience and the number of procedures performed. One study surveyed 181 urologic surgeons at 3 and 12 months following completion of a laparoscopy course that included didactic lectures, live case presentations, simulator training, and a live-animal laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/5\">",
"     5",
"    </a>",
"    ]. Surgeons who performed procedures without additional training were threefold to fivefold more likely to have at least one complication at 3 and 12 months, respectively, than surgeons who sought additional training. In addition, those surgeons in a solo practice or those with a variable surgical assistant were 7.74 and 4.80 times more likely to have had a complication. Therefore, formal training and didactic lectures are important [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/6\">",
"     6",
"    </a>",
"    ], but do not substitute for continued operating room experience with a more experienced laparoscopist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPLICATIONS RELATED TO ENTRY AND PNEUMOPERITONEUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of pertinent surgical anatomy is crucial to avoiding injury during insertion of laparoscopic instruments. In addition, some complications may be related to pneumoperitoneum. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"     \"Abdominal access techniques used in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ELECTROSURGICAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected electrosurgical injuries are discussed below by organ system. General principles of electrosurgery and prevention of electrosurgical complications are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link\">",
"     \"Overview of electrosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VASCULAR INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular injury usually occurs from laceration of the mesenteric vessels during insertion of the primary trocar or Veress needle through the umbilicus. Use of laparoscopic instruments for hemostasis and management of complications of laparoscopic entry are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=see_link&amp;anchor=H16#H16\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\", section on 'Management of hemorrhage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link&amp;anchor=H19386192#H19386192\">",
"     \"Abdominal access techniques used in laparoscopic surgery\", section on 'Vascular injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of general issues of hemorrhage in gynecologic surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BOWEL INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel injury is one of the most serious complications because it may be missed at the time of the initial laparoscopy and any delay increases the risk of fecal peritonitis and death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The golden rule of laparoscopic surgery is that patients gradually get better with each passing hour following the operation. If a patient continues to have pain, especially in the presence of tachycardia or fever, then bowel injury must be suspected and immediate consultation with a general surgeon is indicated. Ileus after laparoscopy is not normal, and warrants thorough patient evaluation. The demonstration of free intra-abdominal air on an upright abdominal radiograph has been used to diagnose a ruptured intraperitoneal viscus. This radiographic sign is generally",
"    <strong>",
"     NOT",
"    </strong>",
"    helpful after laparoscopic surgery because approximately 40 percent of patients will have more than 2 cm of free air at 24 hours postlaparoscopy, despite lack of any clinical evidence of bowel perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/8\">",
"     8",
"    </a>",
"    ]. Free air often may be seen on a radiograph up to a week postoperatively, but the volume should gradually decrease. Increasing amounts of intraabdominal air during the period of observation is concerning. The finding of increasing free intra abdominal air indicates ruptured viscus until proven otherwise. Laparotomy is indicated in this circumstance.",
"   </p>",
"   <p>",
"    Patients may have fecal contamination of the abdominal cavity and still have bowel movements, be ambulatory and not display peritonitis. Repeat open laparoscopy is a consideration in patients in whom there is a high level of concern for possible bowel injury, or the surgeon may go straight to laparotomy.",
"   </p>",
"   <p>",
"    Injury to the bowel may result from insertion of the pneumoperitoneum needle, placement of the laparoscopic trocar, electrosurgical injury, or trauma during dissection. Symptoms from penetrating trauma generally manifest within 12 to 36 hours, but may occur up to five or seven days later. Presumably, patients who present after several days have experienced either delayed necrosis of damaged bowel, or had a leak which temporarily sealed off. Penetrating injuries due to the pneumoperitoneum needle can be managed conservatively and generally do not require any treatment. The vast majority of trocar punctures require only suture reapproximation.",
"   </p>",
"   <p>",
"    Electrosurgical injuries may not become symptomatic for several days. Burn injuries require resection of 1 to 2 cm of viable tissue around the injury site to ensure that all of the damaged tissue has been removed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/9-15\">",
"     9-15",
"    </a>",
"    ]. The resected loop of bowel should be examined by the pathologist to ensure that all of the damaged tissue has been excised; cytologic changes associated with electrothermal injuries can be identified and should not extend all the way to the resected margin. It is important to restore bowel anatomy so that there is no leakage of bowel contents. The techniques used are similar to those employed at laparotomy. Colostomy is rarely indicated, and should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=see_link&amp;anchor=H6#H6\">",
"     \"Complications of gynecologic surgery\", section on 'Bowel injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     URINARY TRACT INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the urinary tract usually occurs to the bladder during secondary trocar insertion. Signs include bloody urine and gas in the urine bag [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/16\">",
"     16",
"    </a>",
"    ]. Bladder injury can be minimized by placement of the secondary trocar under direct visualization and by making certain that the bladder is",
"    <strong>",
"     emptied",
"    </strong>",
"    before trocar placement.",
"   </p>",
"   <p>",
"    Thermal injury to the bladder generally results from dissection during laparoscopic hysterectomy or with dissection and destruction of endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. As with bowel injuries, no treatment is generally required if the bladder is punctured with a pneumoperitoneum needle. In contrast, a perforation due to trocar injury should be sutured if recognized at the time of the initial surgery. If not recognized, the patient will generally present with symptoms of urinary tract injury postoperatively.",
"   </p>",
"   <p>",
"    Ureteral injury is becoming more common as a result of the increasing numbers of laparoscopically-assisted vaginal hysterectomies being performed, although ureteral injury can occur during any operative laparoscopy procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Ureteral identification is the only means of preventing injury; observation of peristalsis is a key component of identification [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/16\">",
"     16",
"    </a>",
"    ]. Dissection and mobilization of the ureter may be required. At the conclusion of a laparoscopic procedure, the surgeon should visualize and confirm the integrity of the ureters, and document this.",
"   </p>",
"   <p>",
"    Thermal ureteral injuries are caused by excessive use of an energy source adjacent to the ureter. These are best managed with resection of the damaged portion and reimplantation of the ureter. If untreated, a genitourinary fistula may develop.",
"   </p>",
"   <p>",
"    Prevention, evaluation, and management of urinary tract injury in gynecologic surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14056?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy may occur postoperatively, primarily from nerve compression as a result of faulty patient positioning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link\">",
"     \"Nerve injury associated with pelvic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injury to the ilioinguinal and iliohypogastric nerves can be avoided by placing incisions above the anterior superior iliac spine, as these nerves travel in the abdominal wall below this level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link&amp;anchor=H11#H11\">",
"     \"Nerve injury associated with pelvic surgery\", section on 'Iliohypogastric and ilioinguinal nerves'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     WOUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed bleeding from trocar sites has been seen, with significant drops in hemoglobin and large abdominal and flank ecchymoses. Intraoperative bleeding may be tamponaded when the trocars and pneumoperitoneum are in place; bleeding typically occurs within one hour of removing the instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/25\">",
"     25",
"    </a>",
"    ]. Clinical manifestations including swelling, pain, ecchymoses of the anterior abdominal wall and external bleeding from the trocar site.",
"   </p>",
"   <p>",
"    Abdominal wall hematomas which are clinically stable on physical examination and by imaging (eg, ultrasonography, computed tomography) can be managed conservatively. The hematoma may drain spontaneously through one or more port site. No intervention is necessary, and drainage will cease spontaneously. Patients should be advised that this may occur. Surgical intervention for suture ligation is usually needed if the hematoma is expanding or becomes abscessed.",
"   </p>",
"   <p>",
"    Delayed hematomas of the abdominal wall, of considerable size, may present two or three days after surgery as purple discoloration of a portion of the abdominal wall",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    back. Presumably, they arise from delayed bleeding from vessels injured in the abdominal wall. CT scans will reveal a large hematoma. Observation and correction of anemia usually suffice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Disruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incisional bowel herniation after laparoscopy appears to be related to more complicated procedures that require multiple ancillary ports, larger diameter ports for specimen removal, and operative instrumentation, such as stapling devices. Increased operative times and greater tissue manipulation may also lead to fascial weakening. The use of fascial screws increases the incision size and may result in greater fascial tissue damage.",
"   </p>",
"   <p>",
"    A survey of members of the American Association of Gynecologic Laparoscopists reported 933 hernias from an estimated 4,385,000 laparoscopic procedures (incidence 21 per 100,000 procedures) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/26\">",
"     26",
"    </a>",
"    ]. Eighteen percent of these hernias occurred despite fascial closure. Similar findings were reported in a multicenter retrospective review that identified 19 herniations despite an attempt to close the fascia at the initial surgery in 9 of 19 cases (43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/27\">",
"     27",
"    </a>",
"    ]. Another multicenter study of 3560 operative laparoscopies found six incisional hernias (incidence 0.17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of herniation is greater for extra-umbilical sites and with use of a 12-mm trocar (3.1 percent) than with a 10-mm trocar (0.23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]; the fascia should be closed for these incisions. Radially expanding trocars expand rather than cut fascia. Although randomized trials found no increased risk of incisional hernia at &ge;10 mm in radially expanded port sites without fascial closure compared with bladed trocars with fascial closure, these studies were underpowered to detect a difference between the two methods [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. A conservative approach is to close &ge;10 mm port sites until these findings are confirmed in larger studies.",
"   </p>",
"   <p>",
"    Clinical manifestations consist of gross disruption of the wound, or presence of a bulge, which is painful if bowel or omentum becomes entrapped. Nausea and vomiting and signs of bowel obstruction may be present, including infarction. Treatment is by secondary closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Port site metastasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Port site metastasis refers to cancer growth in the trocar site after laparoscopic oncology surgery. It has been observed as little as 10 days after a laparoscopy. Port site metastasis occurs after 1 to 2 percent of laparoscopic procedures performed in the presence of intraperitoneal malignancy, especially advanced disease and ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/32\">",
"     32",
"    </a>",
"    ]; this rate is comparable to the rate of wound metastasis after laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/33\">",
"     33",
"    </a>",
"    ]. Purported mechanisms include hematogenous spread or direct contamination by tumor cells, secondary effects from pneumoperitoneum (eg, immune suppression), and surgical technique. These mechanisms have been reviewed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Although it is not clear whether port site metastases can be prevented, a number of preventive measures have been suggested, such as avoidance of laparoscopy in patients with advanced intraperitoneal malignant disease and instillation of agents to prevent tumor growth. If a patient with malignancy is explored after laparoscopy, excision of port sites is a consideration if feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SHOULDER PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative shoulder pain is not uncommon after laparoscopic surgery. It generally considered to be referred pain due to irritation of the diaphragm (by fluid, blood or carbon dioxide) or stretching of the phrenic nerves during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/35\">",
"     35",
"    </a>",
"    ]. Various preventative measures have been attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized trial, patients who underwent a maneuver to remove excess carbon dioxide compared to those who did not had significantly less postoperative shoulder pain (pain scores at 12 hours were 16 versus 30) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/36\">",
"       36",
"      </a>",
"      ]. The maneuver was performed prior to wound closure and with laparoscopic port valves open, the patient was placed in Trendelenburg position (30 degrees), and the anesthesiologist asked to provide positive pressure pulmonary inflation five times.",
"     </li>",
"     <li>",
"      Two randomized trials found that intraperitoneal irrigation with local anesthetic reduced shoulder pain compared to normal saline; preparations used were 50 ml of 0.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      (pain scores 24 versus 44) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/37\">",
"       37",
"      </a>",
"      ] or 10 mL 0.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      in 500 mL saline (42 versus 4 percent reported shoulder pain) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     VULVAR EDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been a few case reports of unilateral vulvar edema after operative laparoscopy. The mechanism is unclear, but the condition is self-limited and resolves with conservative management (ice packs, bladder catheterization, analgesia) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, swelling in this setting can also be related to vascular bleeding and require intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7415/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 50 percent of complications related to gynecologic laparoscopic surgery occur during entry. Injuries to bowel and blood vessels are the most common and most serious complications. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some surgeons prefer a nonlaparoscopic surgical approach in patients with conditions that increase the risk of complications, such as extensive bowel distention, very large pelvic or abdominal masses, extensive",
"      <span class=\"nowrap\">",
"       pelvic/intraabdominal",
"      </span>",
"      adhesions, cardiopulmonary disease, and diaphragmatic hernia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper selection of patients; knowledge of surgical anatomy; placement of trocars under direct vision; decompressing the stomach with a nasogastric tube; and use of open technique, high pressure pneumoperitoneum, disposable laparoscopy",
"      <span class=\"nowrap\">",
"       needles/trocars",
"      </span>",
"      may help to avoid entry injuries. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Complications related to entry and pneumoperitoneum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular injury may not be appreciated immediately because bleeding is often retroperitoneal, rather than into the peritoneal cavity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Vascular injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients gradually get better with each passing hour following the operation. If a patient continues to have pain, especially in the presence of tachycardia or fever, then bowel injury must be suspected. Injury to the bowel may result from insertion of the pneumoperitoneum needle, placement of the laparoscopic trocar, electrosurgical injury, or trauma during dissection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bowel injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injury to the bladder typically occurs during secondary trocar insertion. Signs include bloody urine and gas in the urine bag. Retrograde filling of the bladder with a sterile colored fluid can be used to confirm the diagnosis. The risk of bladder injury can be reduced by placement of the secondary trocar under direct visualization and by making certain that the bladder is empty before trocar placement. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Urinary tract injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureteral identification is the only means of preventing ureteral injury; observation of peristalsis is a key component of identification. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Urinary tract injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal wall hematomas which are clinically stable on physical examination and by imaging can be managed conservatively. The risk of incisional hernia is greater for extra-umbilical sites and with use of trocars &ge;10 mm. It is generally agreed that 5 mm trocar incisions do not require closure, given the low risk of hernia formation; however, large incisions should be closed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Wound'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/1\">",
"      Magrina JF. Complications of laparoscopic surgery. Clin Obstet Gynecol 2002; 45:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/2\">",
"      Chandler JG, Corson SL, Way LW. Three spectra of laparoscopic entry access injuries. J Am Coll Surg 2001; 192:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/3\">",
"      Jansen FW, Kolkman W, Bakkum EA, et al. Complications of laparoscopy: an inquiry about closed- versus open-entry technique. Am J Obstet Gynecol 2004; 190:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/4\">",
"      Bhoyrul S, Vierra MA, Nezhat CR, et al. Trocar injuries in laparoscopic surgery. J Am Coll Surg 2001; 192:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/5\">",
"      See WA, Cooper CS, Fisher RJ. Predictors of laparoscopic complications after formal training in laparoscopic surgery. JAMA 1993; 270:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/6\">",
"      Coleman RL, Muller CY. Effects of a laboratory-based skills curriculum on laparoscopic proficiency: a randomized trial. Am J Obstet Gynecol 2002; 186:836.",
"     </a>",
"    </li>",
"    <li>",
"     Goldberg JM, Chen CCG, Falcone T. Complication of laparoscopic surgery. In: Basic, Advanced, and Robotic Laparoscopic Surgery, Falcone T, Goldberg JM.  (Eds), Saunders Elsevier, Philadelphia 2010. p.221.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/8\">",
"      Farooqui MO, Bazzoli JM. Significance of radiologic evidence of free air following laparoscopy. J Reprod Med 1976; 16:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/9\">",
"      Roopnarinesingh S, Raj-Kumar G, Woo J. Laparoscopic trocar point perforation of the small bowel. Int Surg 1977; 62:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/10\">",
"      Milliken, RA, Milliken, GM. Gastric perforation: rare complications of laparoscopy. NY State J Med 1975; Jan:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/11\">",
"      Endler GC, Moghissi KS. Gastric perforation during pelvic laparoscopy. Obstet Gynecol 1976; 47:40S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/12\">",
"      Esposito JM. Hematoma of the sigmoid colon as a complication of laparoscopy. Am J Obstet Gynecol 1973; 117:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/13\">",
"      Birns MT. Inadvertent instrumental perforation of the colon during laparoscopy: nonsurgical repair. Gastrointest Endosc 1989; 35:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/14\">",
"      Thompson BH, Wheeless CR Jr. Gastrointestinal complications of laparoscopy sterilization. Obstet Gynecol 1973; 41:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/15\">",
"      Shell JH Jr, Myers RC Jr. Small bowel injury after laparoscopic sterilization. Am J Obstet Gynecol 1973; 115:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/16\">",
"      Shirk GJ, Johns A, Redwine DB. Complications of laparoscopic surgery: How to avoid them and how to repair them. J Minim Invasive Gynecol 2006; 13:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/17\">",
"      Georgy FM, Fetterman HH, Chefetz MD. Complication of laparoscopy: two cases of perforated urinary bladder. Am J Obstet Gynecol 1974; 120:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/18\">",
"      Homburg R, Segal T. Perforation of the urinary bladder by the laparoscope. Am J Obstet Gynecol 1978; 130:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/19\">",
"      Deshmukh AS. Laparoscopic bladder injury. Urology 1982; 19:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/20\">",
"      Sherer DM. Inadvertent transvaginal cystotomy during laparoscopy. Int J Gynaecol Obstet 1990; 32:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/21\">",
"      Grainger DA, Soderstrom RM, Schiff SF, et al. Ureteral injuries at laparoscopy: insights into diagnosis, management, and prevention. Obstet Gynecol 1990; 75:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/22\">",
"      Gomel V, James C. Intraoperative management of ureteral injury during operative laparoscopy. Fertil Steril 1991; 55:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/23\">",
"      Woodland MB. Ureter injury during laparoscopy-assisted vaginal hysterectomy with the endoscopic linear stapler. Am J Obstet Gynecol 1992; 167:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/24\">",
"      Kadar N, Lemmerling L. Urinary tract injuries during laparoscopically assisted hysterectomy: causes and prevention. Am J Obstet Gynecol 1994; 170:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/25\">",
"      Fern&aacute;ndez EM, Malag&oacute;n AM, Arteaga I, et al. Conservative treatment of a huge abdominal wall hematoma after laparoscopic appendectomy. J Laparoendosc Adv Surg Tech A 2005; 15:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/26\">",
"      Montz FJ, Holschneider CH, Munro MG. Incisional hernia following laparoscopy: a survey of the American Association of Gynecologic Laparoscopists. Obstet Gynecol 1994; 84:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/27\">",
"      Boike GM, Miller CE, Spirtos NM, et al. Incisional bowel herniations after operative laparoscopy: a series of nineteen cases and review of the literature. Am J Obstet Gynecol 1995; 172:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/28\">",
"      Kadar N, Reich H, Liu CY, et al. Incisional hernias after major laparoscopic gynecologic procedures. Am J Obstet Gynecol 1993; 168:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/29\">",
"      Liu CD, McFadden DW. Laparoscopic port sites do not require fascial closure when nonbladed trocars are used. Am Surg 2000; 66:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/30\">",
"      Bhoyrul S, Payne J, Steffes B, et al. A randomized prospective study of radially expanding trocars in laparoscopic surgery. J Gastrointest Surg 2000; 4:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/31\">",
"      Johnson WH, Fecher AM, McMahon RL, et al. VersaStep trocar hernia rate in unclosed fascial defects in bariatric patients. Surg Endosc 2006; 20:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/32\">",
"      Abu-Rustum NR, Rhee EH, Chi DS, et al. Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. Obstet Gynecol 2004; 103:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/33\">",
"      Ramirez PT, Wolf JK, Levenback C. Laparoscopic port-site metastases: etiology and prevention. Gynecol Oncol 2003; 91:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/34\">",
"      Ost MC, Tan BJ, Lee BR. Urological laparoscopy: basic physiological considerations and immunological consequences. J Urol 2005; 174:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/35\">",
"      Jackson SA, Laurence AS, Hill JC. Does post-laparoscopy pain relate to residual carbon dioxide? Anaesthesia 1996; 51:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/36\">",
"      Phelps P, Cakmakkaya OS, Apfel CC, Radke OC. A simple clinical maneuver to reduce laparoscopy-induced shoulder pain: a randomized controlled trial. Obstet Gynecol 2008; 111:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/37\">",
"      Palmes D, R&ouml;ttgermann S, Classen C, et al. Randomized clinical trial of the influence of intraperitoneal local anaesthesia on pain after laparoscopic surgery. Br J Surg 2007; 94:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/38\">",
"      Cunniffe MG, McAnena OJ, Dar MA, et al. A prospective randomized trial of intraoperative bupivacaine irrigation for management of shoulder-tip pain following laparoscopy. Am J Surg 1998; 176:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/39\">",
"      Pados G, Vavilis D, Pantazis K, et al. Unilateral vulvar edema after operative laparoscopy: a case report and literature review. Fertil Steril 2005; 83:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/40\">",
"      Guven S, Guven ES, Ayhan A. Vulvar edema as a rare complication of laparoscopy. J Am Assoc Gynecol Laparosc 2004; 11:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7415/abstract/41\">",
"      Marcovici I, Shadigian E. Operative laparoscopy and vulvar hematoma: an unusual association. JSLS 2001; 5:87.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3290 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7415=[""].join("\n");
var outline_f7_15_7415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPLICATIONS RELATED TO ENTRY AND PNEUMOPERITONEUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ELECTROSURGICAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VASCULAR INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BOWEL INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      URINARY TRACT INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      WOUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Disruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Port site metastasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SHOULDER PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      VULVAR EDEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=related_link\">",
"      Complications of gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=related_link\">",
"      Devices for dissection and hemostasis in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=related_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14056?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_15_7416="Exhaled nitric oxide analysis";
var content_f7_15_7416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exhaled nitric oxide analysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7416/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7416/contributors\">",
"     Aaron Deykin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7416/contributors\">",
"     Anthony F Massaro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7416/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7416/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7416/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/15/7416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 15, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide (NO) is a molecular gas previously considered to have a health-related role only in the context of its formation from the combustion of fossil fuels and its contribution to air pollution. However, this view has been greatly modified since the discovery in 1987 that the free radical NO was the previously uncharacterized endothelial-derived relaxing factor. It has now become clear that NO plays an important role in most human organ systems.",
"   </p>",
"   <p>",
"    Within the respiratory system, NO regulates vascular and bronchial tone (promoting dilation of both vessels and airway), helps to facilitate the coordinated beating of ciliated epithelial cells, and is an important neurotransmitter for non-adrenergic, non-cholinergic neurons that run in the bronchial wall [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. This molecule can be detected in exhaled gas in concentrations, which vary in health and disease.",
"   </p>",
"   <p>",
"    The biology of NO, techniques available for measuring this gas in exhaled breath, and potential uses of these measurements in clinical practice will be reviewed here. The therapeutic use of inhaled NO is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=see_link\">",
"     \"Inhaled nitric oxide in adults with pulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link\">",
"     \"Novel therapies for the acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FORMATION OF NO",
"    </span>",
"    &nbsp;&mdash;&nbsp;In biological systems, NO is formed by the action of one of the isoforms of the enzyme nitric oxide synthase (NOS). Three such isoforms have been identified and are termed type I or neuronal cell NOS (nNOS), type II or inducible NOS (iNOS), and type III or endothelial cell NOS (eNOS) (",
"    <a class=\"graphic graphic_table graphicRef68181 \" href=\"UTD.htm?14/21/14683\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Although these enzymes are distinct proteins encoded by genes on disparate chromosomes, all three catalyze the adduction of the guanidino nitrogen of the amino acid arginine to molecular oxygen, yielding NO and water (",
"    <a class=\"graphic graphic_figure graphicRef79786 \" href=\"UTD.htm?27/52/28494\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Regulation of NOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the three isoforms of NOS catalyze the same reaction, regulation of the activity of these isozymes occurs through distinct processes. Both nNOS and eNOS are usually constitutively active and produce low amounts of NO, with output varying with changes in the intracellular calcium concentration. In contrast, iNOS binds calcium so avidly that its function is not influenced by calcium fluxes within the physiologic range. While not constitutively active in most settings, it has the capacity to generate large quantities of NO when transcriptionally upregulated by the inflammatory cytokines tumor necrosis factor-alpha (TNFa), interleukin 1-beta (IL-1B), and interferon-gamma (IFN-gamma) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In vitro evidence suggests that this upregulation can be abolished by glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Location of NOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cellular location of the various NOS isoforms has been investigated using immunohistochemical and DNA hybridization techniques. In the human lung, nNOS localizes to airway epithelium and likely to the submucosal nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], iNOS has been documented in airway epithelial and inflammatory cells, and eNOS exists in the pulmonary epithelium and the vascular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study using immunohistochemical techniques has demonstrated that epithelial cells within the airways of asthmatic patients have increased staining for iNOS when compared with cells obtained from nonasthmatics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/16\">",
"     16",
"    </a>",
"    ]. Since iNOS is inducible by inflammatory cytokines and is inhibited by glucocorticoids, this finding provides circumstantial evidence to support the notion that iNOS within airway epithelial cells is the source of the increased NO encountered in asthma.",
"   </p>",
"   <p>",
"    In contrast, evidence derived from mice with specific deletions of one of the three NOS isoforms has indicated that, while iNOS contributes significantly to the total NOS activity after allergen exposure, nNOS mediates the majority of the post-exposure airway hyperreactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/17\">",
"     17",
"    </a>",
"    ]. The important contribution of nNOS to the NO measured in the expirate is further underscored by data which demonstrate that mice with a deletion of nNOS have 40 percent lower concentrations of NO in their expirate than wild type animals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Source of exhaled NO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because nitric oxide is formed by multiple mechanisms and in various types of cells, the precise anatomic source of exhaled NO (eNO) is not known. Early studies suggested that because the nasal sinuses contain very high levels of NO (&gt;1000 ppb), the NO in orally expired gas was likely to represent contamination of exhaled gas with NO derived from the sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. However, subsequent studies using bronchoscopic techniques to isolate the lower airway from nasal gas have demonstrated that the concentrations of NO in gas derived exclusively from the lower airway are comparable to those obtained in the expirate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, it appears that the majority of eNO originates below the glottis. Mathematical models using simultaneous high resolution recordings of eNO and flow rate have similarly suggested that the majority of NO is excreted from the larger central airways [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFECTS OF NO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of altered NO homeostasis has been studied in various animal and human models, and involves all anatomic compartments of the lung. Notable findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After stimulation by endotoxin and cytokines, alveolar macrophages synthesize NO to bolster host defense [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/25-27\">",
"       25-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The vasodilating effects of NO contribute to the development of neurogenic edema, which can worsen asthmatic airway obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NO is easily oxidized in biological systems to peroxynitrite (OONO-), a potent epithelial toxin, which may directly participate in the epithelial damage characteristic of severe asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NO may promote the preferential proliferation of Th2 lymphocytes over Th1 lymphocytes. This favors the overproduction of IL-4 and IL-5 commonly noted in asthmatics [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A permissive effect on the Th2 phenotype has been further suggested by data indicating that NO inhibits apoptosis of eosinophils in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF EXHALED NO",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was first demonstrated in 1991 that NO could be detected in the exhaled gas of animals and humans in the range of 3 to 20 parts per billion (ppb) by using chemiluminescence analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/34\">",
"     34",
"    </a>",
"    ]. Chemiluminescence analysis allows determination of NO concentration in the gas phase by reacting NO in the sample with ozone to produce nitrogen dioxide in an excited state. As nitrogen dioxide moves to a relaxed state, light is emitted in a stoichiometric relationship with the amount of NO present in the gas sample. Most studies reported in the literature use chemiluminescence to measure eNO concentrations.",
"   </p>",
"   <p>",
"    The majority of methods used for collection of the expirate can be divided into one of two types - \"online\" and \"offline.\" The term \"offline measurement\" is used to describe methods in which the subject exhales either single or multiple breaths into a NO impermeable reservoir. This reservoir is sealed and subsequently brought to the analyzer for NO measurement. Alternatively, \"online measurement\" involves sampling gas expired directly into the NO analyzer. With this technique, gas samples from various compartments of the exhaled volume can be selectively analyzed.",
"   </p>",
"   <p>",
"    Expiratory flow, contamination by nasal NO, and dead space volume can all affect measurement of eNO [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/35\">",
"     35",
"    </a>",
"    ]. A number of other factors that can influence eNO results are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef64185 \" href=\"UTD.htm?43/26/44460\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approval of an eNO monitoring device may increase the clinical availability and use of this technology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/37\">",
"     37",
"    </a>",
"    ]. Most school aged children are able to perform the test [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/24,38\">",
"     24,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reference range",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reference range is sometimes referred to as the normal range, although this may be misleading because healthy individuals sometimes fall outside the range and individuals with a certain condition occasionally fall within the range [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/39-43\">",
"     39-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One cross-sectional study (n = 2319) calculated a reference range of 7.8 to 41.1 ppb, defined as the 90 percent confidence interval for an individual prediction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/40\">",
"     40",
"    </a>",
"    ]. However, the reference range varies considerably according to the age, sex, atopy status, and smoking status of the individual, suggesting that different reference ranges should exist for individuals with different combinations of these characteristics (",
"    <a class=\"graphic graphic_table graphicRef57833 \" href=\"UTD.htm?28/36/29260\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society Clinical Practice Guideline suggests that cut points be used in the analysis of eNO results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/45\">",
"     45",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low eNO less than 25 ppb in adults and less than 20 ppb in children implies noneosinophilic airway inflammation or the absence of airway inflammation.",
"     </li>",
"     <li>",
"      A high eNO greater than 50 ppb in adults and 35 ppb in children or a rising eNO with a greater than 40 percent change from a previously stable level implies uncontrolled or deteriorating eosinophilic airway inflammation.",
"     </li>",
"     <li>",
"      Values of eNO between 25 and 50 ppb in adults (20 to 35 ppb in children) should be interpreted cautiously with reference to the clinical situation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     USE IN ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observations suggest eNO measurement may have a role in the diagnosis and management of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/45-54\">",
"     45-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with asthma have higher concentrations of NO in their expirate than do nonasthmatic subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/55\">",
"       55",
"      </a>",
"      ]. In addition, exhaled NO levels rise in association with acute airway inflammation, sputum eosinophilia, viral upper respiratory infections, and other clinical parameters associated with asthmatic control [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/55-60\">",
"       55-60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhalation of inflammatory stimuli increases eNO, including allergens, plicatic acid (the etiologic agent of Western red cedar asthma), isocyanates, and hyperventilation of cold-dry air [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/61-65\">",
"       61-65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levels of eNO may correlate with bronchial reactivity and the number of eosinophils in induced sputum in patients with stable asthma not using glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/66,67\">",
"       66,67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administration of glucocorticoids or leukotriene receptor antagonists, agents that decrease asthmatic inflammation, results in reductions in eNO [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/55,58,59\">",
"       55,58,59",
"      </a>",
"      ]. In one report, for example, asthmatic subjects receiving treatment with inhaled glucocorticoids had lower mean eNO concentrations than those not treated with these agents (10.9 versus 19.4 ppb) (",
"      <a class=\"graphic graphic_figure graphicRef69366 \" href=\"UTD.htm?32/21/33117\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability of serial eNO monitoring to predict asthma control following changes in therapy has been assessed in adults and children with asthma with conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/47,52-54,68-71\">",
"     47,52-54,68-71",
"    </a>",
"    ]. In addition, randomized trials examining the value of eNO measurements to guide asthma management have yielded conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial (n = 97), care guided by eNO measurements achieved similar asthma control at lower glucocorticoid doses, compared to clinical practice guideline-based management [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A larger trial (n = 546), comparing an eNO based algorithm with a conventional guidelines, found no improvement in asthma control; overall, the eNO group received higher doses of inhaled glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third trial (n = 118) found that eNO-guided therapy had little impact on the frequency of asthma exacerbations or the amount of inhaled glucocorticoids used, compared to clinical practice guideline-based management [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial examining eNO-based asthma care during pregnancy, 220 pregnant subjects with asthma were randomly assigned to eNO-based or symptom-based algorithms for asthma management [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/74\">",
"       74",
"      </a>",
"      ]. The eNO based algorithm resulted in a significantly lower exacerbation rate (incidence rate ratio 0.496, 95% CI 0.325-0.755). At the end of the study, more subjects in the eNO group were taking inhaled glucocorticoids compared with the symptom based group, but the mean dose of inhaled glucocorticoids was lower. In addition, more patients in the eNO group were using a long-acting beta agonist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationships among airway inflammation, eNO, and asthma are still not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/77\">",
"     77",
"    </a>",
"    ]. As an example, airway acidification (mostly due to reflux) may lead to nonenzymatic NO formation, independent of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/78\">",
"     78",
"    </a>",
"    ]. In addition, although the known effects of NO on the human airway support some role for NO in the pathobiology of asthma, it is also possible that eNO is marker, rather than a cause of, inflammation. Widespread use of eNO monitoring will also require standardization of measurement techniques and generation of reference values, which probably vary as a function of age and height [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     USE IN OTHER RESPIRATORY DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases other than asthma are associated with altered levels of eNO [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/35\">",
"     35",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bronchiectasis, cystic fibrosis, and sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with cystic fibrosis (CF) have lower eNO levels than appropriately matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. This may be due to elevated arginase activity; arginase competes for L-arginine, the substrate of nitric oxide synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/82\">",
"     82",
"    </a>",
"    ]. In contrast, one study found that patients with non-CF bronchiectasis had elevated levels of eNO, and these levels were correlated with the degree of abnormality apparent on chest CT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/83\">",
"     83",
"    </a>",
"    ]. Whether this discrepancy relates to disease activity, especially coexistent infection, is not yet clear. Patients with sarcoidosis also demonstrate increased eNO; however, these changes do not correlate to disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chronic obstructive pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;eNO levels are minimally elevated in stable COPD, but may increase with more severe disease and during exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. In patients with COPD, eNO levels may be useful in establishing the presence of reversible airflow obstruction and determining glucocorticoid responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nonasthmatic eosinophilic bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with nonasthmatic eosinophilic bronchitis (NAEB), sputum eosinophils and exhaled NO are increased in a range similar to patients with asthma. In a study of 117 patients with cough lasting three weeks or longer, eNO was elevated in 21 patients believed to have NAEB by increased sputum eosinophil count and lack of bronchial hyperresponsiveness to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge (to exclude asthma) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/91\">",
"     91",
"    </a>",
"    ]. The positive and negative predictive values of eNO for detecting NAEB were 47 and 95 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Upper respiratory infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study of patients without underlying pulmonary disease, viral upper respiratory infections resulted in increased eNO [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/92\">",
"     92",
"    </a>",
"    ]. These levels were dramatically reduced when rechecked three weeks later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Low exhaled NO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions associated with low eNO levels include pulmonary hypertension, hypothermia, primary ciliary dyskinesia, bronchopulmonary dysplasia, as well as the use of alcohol, tobacco, caffeine, and other drugs (",
"    <a class=\"graphic graphic_table graphicRef64185 \" href=\"UTD.htm?43/26/44460\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7416/abstract/15,93-97\">",
"     15,93-97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the future, measurement of exhaled nitric oxide (eNO), a simple, noninvasive test, could be used to aid in the diagnosis of asthma and potentially monitor the inflammatory status of the asthmatic airway during treatment with antiinflammatory medications. Although it is possible that therapeutic agents could be titrated to the lowest doses that suppress elevated levels of eNO, the role of eNO in the ongoing care of patients with established asthma is uncertain. Moreover, due to the expense of the chemiluminescence NO analyzer, measurement of eNO is largely restricted to research hospitals and large medical centers at the present time.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/1\">",
"      Belvisi MG, Ward JK, Mitchell JA, Barnes PJ. Nitric oxide as a neurotransmitter in human airways. Arch Int Pharmacodyn Ther 1995; 329:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/2\">",
"      Jain B, Rubinstein I, Robbins RA, et al. Modulation of airway epithelial cell ciliary beat frequency by nitric oxide. Biochem Biophys Res Commun 1993; 191:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/3\">",
"      Belvisi MG, Stretton CD, Yacoub M, Barnes PJ. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur J Pharmacol 1992; 210:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/4\">",
"      Blitzer ML, Loh E, Roddy MA, et al. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol 1996; 28:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/5\">",
"      Combes X, Mazmanian M, Gourlain H, Herv&eacute; P. Effect of 48 hours of nitric oxide inhalation on pulmonary vasoreactivity in rats. Am J Respir Crit Care Med 1997; 156:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/6\">",
"      M&eacute;lot C, Vermeulen F, Maggiorini M, et al. Site of pulmonary vasodilation by inhaled nitric oxide in microembolic lung injury. Am J Respir Crit Care Med 1997; 156:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/7\">",
"      Buga GM, Ignarro LJ. Electrical field stimulation causes endothelium-dependent and nitric oxide-mediated relaxation of pulmonary artery. Am J Physiol 1992; 262:H973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/8\">",
"      Que LG, Yang Z, Stamler JS, et al. S-nitrosoglutathione reductase: an important regulator in human asthma. Am J Respir Crit Care Med 2009; 180:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/9\">",
"      Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994; 78:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/10\">",
"      Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994; 78:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/11\">",
"      Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994; 149:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/12\">",
"      Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 1990; 87:10043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/13\">",
"      Asano K, Chee CB, Gaston B, et al. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci U S A 1994; 91:10089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/14\">",
"      Kobzik L, Bredt DS, Lowenstein CJ, et al. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 1993; 9:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/15\">",
"      Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/16\">",
"      Hamid Q, Springall DR, Riveros-Moreno V, et al. Induction of nitric oxide synthase in asthma. Lancet 1993; 342:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/17\">",
"      De Sanctis GT, MacLean JA, Hamada K, et al. Contribution of nitric oxide synthases 1, 2, and 3 to airway hyperresponsiveness and inflammation in a murine model of asthma. J Exp Med 1999; 189:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/18\">",
"      De Sanctis GT, Mehta S, Kobzik L, et al. Contribution of type I NOS to expired gas NO and bronchial responsiveness in mice. Am J Physiol 1997; 273:L883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/19\">",
"      Lundberg JO, Weitzberg E, Nordvall SL, et al. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. Eur Respir J 1994; 7:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/20\">",
"      Lundberg JO, Weitzberg E, Rinder J, et al. Calcium-independent and steroid-resistant nitric oxide synthase activity in human paranasal sinus mucosa. Eur Respir J 1996; 9:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/21\">",
"      Lundberg JO, Rinder J, Weitzberg F, et al. Heavy physical exercise decreases nitric oxide levels in the nasal airways in humans. Acta Physiol Scand 1997; 159:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/22\">",
"      Massaro AF, Mehta S, Lilly CM, et al. Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects. Am J Respir Crit Care Med 1996; 153:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/23\">",
"      Hyde RW, Geigel EJ, Olszowka AJ, et al. Determination of production of nitric oxide by lower airways of humans--theory. J Appl Physiol 1997; 82:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/24\">",
"      Paraskakis E, Brindicci C, Fleming L, et al. Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma. Am J Respir Crit Care Med 2006; 174:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/25\">",
"      Robbins RA, Springall DR, Warren JB, et al. Inducible nitric oxide synthase is increased in murine lung epithelial cells by cytokine stimulation. Biochem Biophys Res Commun 1994; 198:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/26\">",
"      Jorens PG, Van Overveld FJ, Bult H, et al. L-arginine-dependent production of nitrogen oxides by rat pulmonary macrophages. Eur J Pharmacol 1991; 200:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/27\">",
"      Liu HW, Anand A, Bloch K, et al. Expression of inducible nitric oxide synthase by macrophages in rat lung. Am J Respir Crit Care Med 1997; 156:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/28\">",
"      Ialenti A, Ianaro A, Moncada S, Di Rosa M. Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol 1992; 211:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/29\">",
"      Kuo HP, Liu S, Barnes PJ. The effect of endogenous nitric oxide on neurogenic plasma exudation in guinea-pig airways. Eur J Pharmacol 1992; 221:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/30\">",
"      Brunelli L, Crow JP, Beckman JS. The comparative toxicity of nitric oxide and peroxynitrite to Escherichia coli. Arch Biochem Biophys 1995; 316:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/31\">",
"      Wizemann TM, Gardner CR, Laskin JD, et al. Production of nitric oxide and peroxynitrite in the lung during acute endotoxemia. J Leukoc Biol 1994; 56:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/32\">",
"      Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunol Today 1995; 16:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/33\">",
"      Hebestreit H, Dibbert B, Balatti I, et al. Disruption of fas receptor signaling by nitric oxide in eosinophils. J Exp Med 1998; 187:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/34\">",
"      Gustafsson LE, Leone AM, Persson MG, et al. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun 1991; 181:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/35\">",
"      Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/36\">",
"      American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/37\">",
"      Silkoff PE, Carlson M, Bourke T, et al. The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J Allergy Clin Immunol 2004; 114:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/38\">",
"      Buchvald F, Baraldi E, Carraro S, et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. J Allergy Clin Immunol 2005; 115:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/39\">",
"      Smith AD, Cowan JO, Taylor DR. Exhaled nitric oxide levels in asthma: Personal best versus reference values. J Allergy Clin Immunol 2009; 124:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/40\">",
"      Travers J, Marsh S, Aldington S, et al. Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am J Respir Crit Care Med 2007; 176:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/41\">",
"      Michils A, Louis R, Pech&eacute; R, et al. Exhaled nitric oxide as a marker of asthma control in smoking patients. Eur Respir J 2009; 33:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/42\">",
"      Scott M, Raza A, Karmaus W, et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax 2010; 65:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/43\">",
"      Gelb AF, George SC, Camacho F, et al. Increased nitric oxide concentrations in the small airway of older normal subjects. Chest 2011; 139:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/44\">",
"      Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count &ge;3% in a cohort of unselected patients with asthma. Thorax 2010; 65:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/45\">",
"      Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/46\">",
"      Berkman N, Avital A, Breuer R, et al. Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 2005; 60:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/47\">",
"      Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005; 60:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/48\">",
"      Michils A, Baldassarre S, Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J 2008; 31:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/49\">",
"      Pavord ID, Shaw D. The use of exhaled nitric oxide in the management of asthma. J Asthma 2008; 45:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/50\">",
"      Sivan Y, Gadish T, Fireman E, Soferman R. The use of exhaled nitric oxide in the diagnosis of asthma in school children. J Pediatr 2009; 155:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/51\">",
"      Guida G, Rolla G, Badiu I, et al. Determinants of exhaled nitric oxide in chronic rhinosinusitis. Chest 2010; 137:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/52\">",
"      Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010; 138:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/53\">",
"      Sippel JM, Holden WE, Tilles SA, et al. Exhaled nitric oxide levels correlate with measures of disease control in asthma. J Allergy Clin Immunol 2000; 106:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/54\">",
"      Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol 2003; 111:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/55\">",
"      Massaro AF, Gaston B, Kita D, et al. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 1995; 152:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/56\">",
"      Strunk RC, Szefler SJ, Phillips BR, et al. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 2003; 112:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/57\">",
"      Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996; 153:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/58\">",
"      Sandrini A, Ferreira IM, Gutierrez C, et al. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest 2003; 124:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/59\">",
"      Tsujino I, Nishimura M, Kamachi A, et al. Exhaled nitric oxide--is it really a good marker of airway inflammation in bronchial asthma? Respiration 2000; 67:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/60\">",
"      Dweik RA, Sorkness RL, Wenzel S, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010; 181:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/61\">",
"      Kharitonov SA, O'Connor BJ, Evans DJ, Barnes PJ. Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. Am J Respir Crit Care Med 1995; 151:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/62\">",
"      Deykin A, Halpern O, Massaro AF, et al. Expired nitric oxide after bronchoprovocation and repeated spirometry in patients with asthma. Am J Respir Crit Care Med 1998; 157:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/63\">",
"      Obata H, Dittrick M, Chan H, Chan-Yeung M. Sputum eosinophils and exhaled nitric oxide during late asthmatic reaction in patients with western red cedar asthma. Eur Respir J 1999; 13:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/64\">",
"      Ferrazzoni S, Scarpa MC, Guarnieri G, et al. Exhaled nitric oxide and breath condensate ph in asthmatic reactions induced by isocyanates. Chest 2009; 136:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/65\">",
"      Jackson DJ, Virnig CM, Gangnon RE, et al. Fractional exhaled nitric oxide measurements are most closely associated with allergic sensitization in school-age children. J Allergy Clin Immunol 2009; 124:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/66\">",
"      Jatakanon A, Lim S, Kharitonov SA, et al. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/67\">",
"      Warke TJ, Fitch PS, Brown V, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax 2002; 57:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/68\">",
"      Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001; 164:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/69\">",
"      Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004; 169:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/70\">",
"      Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/71\">",
"      de Jongste JC, Carraro S, Hop WC, et al. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009; 179:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/72\">",
"      Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008; 372:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/73\">",
"      Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007; 176:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/74\">",
"      Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/75\">",
"      Petsky HL, Cates CJ, Li A, et al. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2009; :CD006340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/76\">",
"      Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/77\">",
"      Franklin PJ, Stick SM, Le Sou&euml;f PN, et al. Measuring exhaled nitric oxide levels in adults: the importance of atopy and airway responsiveness. Chest 2004; 126:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/78\">",
"      Hunt JF, Fang K, Malik R, et al. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med 2000; 161:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/79\">",
"      Smith AD, Taylor DR. Is exhaled nitric oxide measurement a useful clinical test in asthma? Curr Opin Allergy Clin Immunol 2005; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/80\">",
"      Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997; 24:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/81\">",
"      Ojoo JC, Mulrennan SA, Kastelik JA, et al. Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis. Thorax 2005; 60:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/82\">",
"      Grasemann H, Schwiertz R, Matthiesen S, et al. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 2005; 172:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/83\">",
"      Kharitonov SA, Wells AU, O'Connor BJ, et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med 1995; 151:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/84\">",
"      Ziora D, Kaluska K, Kozielski J. An increase in exhaled nitric oxide is not associated with activity in pulmonary sarcoidosis. Eur Respir J 2004; 24:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/85\">",
"      Moodley YP, Chetty R, Lalloo UG. Nitric oxide levels in exhaled air and inducible nitric oxide synthase immunolocalization in pulmonary sarcoidosis. Eur Respir J 1999; 14:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/86\">",
"      Maziak W, Loukides S, Culpitt S, et al. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/87\">",
"      Rutgers SR, van der Mark TW, Coers W, et al. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax 1999; 54:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/88\">",
"      Ansarin K, Chatkin JM, Ferreira IM, et al. Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function. Eur Respir J 2001; 17:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/89\">",
"      Brindicci C, Ito K, Resta O, et al. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J 2005; 26:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/90\">",
"      Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/91\">",
"      Oh MJ, Lee JY, Lee BJ, Choi DC. Exhaled nitric oxide measurement is useful for the exclusion of nonasthmatic eosinophilic bronchitis in patients with chronic cough. Chest 2008; 134:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/92\">",
"      Kharitonov SA, Yates D, Barnes PJ. Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J 1995; 8:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/93\">",
"      Girgis RE, Champion HC, Diette GB, et al. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 2005; 172:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/94\">",
"      Corbelli R, Bringolf-Isler B, Amacher A, et al. Nasal nitric oxide measurements to screen children for primary ciliary dyskinesia. Chest 2004; 126:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/95\">",
"      Kharitonov SA, Robbins RA, Yates D, et al. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995; 152:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/96\">",
"      Bruce C, Yates DH, Thomas PS. Caffeine decreases exhaled nitric oxide. Thorax 2002; 57:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7416/abstract/97\">",
"      Baraldi E, Bonetto G, Zacchello F, Filippone M. Low exhaled nitric oxide in school-age children with bronchopulmonary dysplasia and airflow limitation. Am J Respir Crit Care Med 2005; 171:68.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 542 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7416=[""].join("\n");
var outline_f7_15_7416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FORMATION OF NO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Regulation of NOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Location of NOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Source of exhaled NO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFECTS OF NO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MEASUREMENT OF EXHALED NO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reference range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      USE IN ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      USE IN OTHER RESPIRATORY DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bronchiectasis, cystic fibrosis, and sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nonasthmatic eosinophilic bronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Upper respiratory infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Low exhaled NO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/542|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/52/28494\" title=\"figure 1\">",
"      Formation of NO by NOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/21/33117\" title=\"figure 2\">",
"      Expired NO in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/542|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/21/14683\" title=\"table 1\">",
"      Characteristics of NOS isoforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/26/44460\" title=\"table 2\">",
"      Factors affecting exhaled NO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/36/29260\" title=\"table 3\">",
"      Reference range eNO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=related_link\">",
"      Inhaled nitric oxide in adults with pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_15_7417="Management of inflight medical emergencies on commercial airlines";
var content_f7_15_7417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of inflight medical emergencies on commercial airlines",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7417/contributors\">",
"     Matthew Prout, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7417/contributors\">",
"     Jeffrey R Pine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7417/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7417/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7417/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7417/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/15/7417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflight medical emergencies are increasing due to the steadily rising number of air travelers, the aging of the US and European populations, and the increasing mobility of people with acute and chronic illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Physician passengers may suddenly find themselves in a difficult environment, in front of many onlookers, managing conditions they do not normally treat, with unfamiliar equipment. There are no universal guidelines for managing inflight medical emergencies, but there are unique considerations. This topic will review the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epidemiology",
"     </li>",
"     <li>",
"      Cabin environment",
"     </li>",
"     <li>",
"      Airline medical emergency protocols",
"     </li>",
"     <li>",
"      Resources aboard an aircraft",
"     </li>",
"     <li>",
"      Management of common emergencies",
"     </li>",
"     <li>",
"      Liability and legal protection for Good Samaritans",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening of patients for air travel is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=see_link\">",
"     \"Patient assessment for air travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are nearly two billion US and overseas air travelers each year [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2\">",
"     2",
"    </a>",
"    ]. Inflight medical emergencies occur at a rate of 20 to 100 per million passengers, with a death rate of 0.1 to 1 per million [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The precise incidence of inflight medical emergencies is unknown because there is no uniform or required reporting system, and flight crews do not routinely report minor inflight medical incidents that do not require ground medical support [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few studies have looked at the number of activations of ground-based emergency medical services for passengers arriving at a given airport. The combined data suggest an incidence of 21 to 25 emergencies per million passengers with 0.1 to 0.3 deaths per million passengers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/4-6,8,9\">",
"     4-6,8,9",
"    </a>",
"    ]. Other studies examined all inflight emergencies that occurred on all flights of a specific airline, or that generated a call from the airplane to ground-based medical advisors. As an example, from 1998 to 1999 British Airways had 92 emergencies per million passengers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/10\">",
"     10",
"    </a>",
"    ]. Seventy percent of these were handled by the flight crew, leaving about 28 incidents per million passengers that would have generated a call for ground-based medical advice. Air France flights made 1.9 calls to ground-based physicians per million passengers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/11\">",
"     11",
"    </a>",
"    ]. A later study found that nine percent of inflight incidents prompted a call for ground-based medical advice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/12\">",
"     12",
"    </a>",
"    ]. These data suggest that most inflight medical events are not serious and are handled adequately by airline crews.",
"   </p>",
"   <p>",
"    Severe emergencies, however, are increasing, and have more than doubled in the last decade [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/13\">",
"     13",
"    </a>",
"    ]. The Air France study, which covered the years from 1989 to 1999, noted that 35 percent of all calls recorded over the 10-year period were made in the final two years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/11\">",
"     11",
"    </a>",
"    ]. These data support the supposition that more people at risk for inflight medical emergencies are flying.",
"   </p>",
"   <p>",
"    The most common medical complaints to airplane crews include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastrointestinal",
"     </li>",
"     <li>",
"      Traumatic",
"     </li>",
"     <li>",
"      Cardiac",
"     </li>",
"     <li>",
"      Neurologic",
"     </li>",
"     <li>",
"      Respiratory",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiac, neurologic, and respiratory complaints comprise the more serious emergencies, as defined by aircraft diversion or use of ground-based medical assistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1,6,10,11,14-16\">",
"     1,6,10,11,14-16",
"    </a>",
"    ]. Among these, cardiac emergencies are most common and account for the largest number of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A medical professional is present for 40 to 70 percent of inflight medical emergencies, and a doctor is present in 30 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/10,15,17\">",
"     10,15,17",
"    </a>",
"    ]. These numbers may be higher; fear of liability prevents some clinicians from intervening [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Liability and legal protection for good samaritans'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CABIN ENVIRONMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflight medical emergencies may occur because the unique physiologic stresses of air travel, including those caused by the conditions of the aircraft cabin, exacerbate a passenger's chronic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reduced oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercial aircraft are pressurized during flight because passengers could not survive the low atmospheric pressure at the usual cruising altitude, which is commonly maintained at 30,000 to 40,000 feet (approximately 9,100 to 12,200 meters). It is impractical to maintain cabin pressure at sea level pressure (by flying at lower altitudes) because of aircraft weight and fuel economy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, the aircraft cabin is pressurized typically to the equivalent of approximately 4000 to 8000 feet (approximately 1400 to 2500 meters) above sea level, and the United States Federal Aviation Administration (FAA) specifies that an 8000 foot environment be maintained even at the highest operating altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/20\">",
"     20",
"    </a>",
"    ]. During shorter flights (&lt;750 miles, or 1200 km), cabins are pressurized to the equivalent of lower altitudes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The barometric pressure drops at this relative altitude from a normal sea level value of 760 mmHg to approximately 560 mmHg. As a result, the PaO2 in normal individuals drops from a baseline of around 95 mmHg at sea level to a PaO2 of 50 to 60 mmHg inside a cabin pressurized at 8000 feet (2500 meters) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21\">",
"     21",
"    </a>",
"    ]. In one study, the oxygen saturations of healthy passengers were measured and showed a decline from 99 percent before take-off to 94 percent during flight [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/22\">",
"     22",
"    </a>",
"    ]. This drop in arterial blood oxygen saturation occurs along the flat portion of the oxyhemoglobin dissociation curve and is usually not noticeable to healthy adults.",
"   </p>",
"   <p>",
"    Passengers may respond to this relatively hypoxic environment by increasing their heart rate, cardiac output, respiratory rate, and respiratory volume. Some may experience mild fatigue. In individuals with cardiopulmonary disease, however, compensation can be insufficient. For them, a relatively small drop in oxygen saturation can occur on the steep part of the oxyhemoglobin dissociation curve, severely compromising their cardiopulmonary reserves and precipitating a medical emergency, such as cardiac ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2,21,23,24\">",
"     2,21,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Air pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Boyle's Law (P x V = P' x V') explains how a set amount of air trapped in a container or viscus will expand to occupy more space at a lower barometric pressure. The diminished air pressure during flight at 8000 feet (2500 meters) can lead to the expansion of gas up to 30 percent compared with sea level [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2,25\">",
"     2,25",
"    </a>",
"    ]. A medical emergency can ensue if the expanding gas is constrained within a confined space such as the pleural cavity, the middle ear, sinuses, a medical device, or another body cavity after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most passengers have experienced discomfort due to expanded air in the middle ear, and they equilibrate pressures by yawning or performing a valsalva maneuver. Chewing gum and frequent swallowing, or for infants a bottle or pacifier to suck on, during ascent and descent can limit discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failure to equilibrate pressures in the middle ear (barotitis media) or paranasal sinuses (barosinusitis) can cause pain, tinnitus, vertigo, hearing loss, and rupture of the tympanic membrane. This typically occurs on descent and may be caused by middle ear infections, effusions, acute or chronic sinusitis, and allergies. The change in barometric pressure can also cause a toothache (barodontalgia) in those with dental disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of scuba diving\", section on 'Dental barotrauma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expansion of trapped gas in the lungs can cause a pneumothorax, especially in individuals with COPD, cystic fibrosis, or recent thoracic surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35271?source=see_link\">",
"     \"Pneumothorax and air travel\"",
"    </a>",
"    .) Pressure can also build in the hollow organs of the GI tract and may cause abdominal distention, pain, and nausea. Expanding intestinal gas may cause dehiscence of surgical wounds, hemorrhage, or bowel perforation in air travelers with recent abdominal surgery complicated by ileus or those with small or large bowel obstruction. Passengers with recent central nervous system or ophthalmologic surgery may also be susceptible to problems associated with the expansion of trapped gas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gas expansion can also affect medical devices with pneumatic components, for example, urinary catheters, feeding tubes, pneumatic splints, and the air-filled cuffs of tracheostomy tubes. Instilling water instead of air can avert these problems [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21\">",
"     21",
"    </a>",
"    ]. Feeding and infusion tubes must be capped off during ascent and descent to prevent introducing air into a vein or hollow viscus. Releasing air from inflatable devices may reduce overexpansion, which could cause local trauma or rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2,21\">",
"     2,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Air quality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cabin air is very dry, usually between 10 and 20 percent humidity; optimal humidity ranges from 40 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. Low humidity can dry the skin, corneas, and airway passages, triggering respiratory problems, especially in patients with asthma or COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. Insensible water loss in the desiccated cabin environment, combined with diminished fluid intake during a long flight, can cause dehydration. These factors can contribute to thick mucus in patients with tracheostomy tubes or transtracheal oxygen catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Transmission of airborne pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aircraft's air conditioning and ventilation system is able to maintain low bacteria and fungi counts in the cabin. There are reports, however, of individuals contracting tuberculosis, influenza, measles, smallpox, and severe acute respiratory syndrome (SARS) aboard commercial flights [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21,27-29\">",
"     21,27-29",
"    </a>",
"    ]. Risk of infection is greatest on flights longer than eight hours and among passengers seated within two rows of the infected passenger [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21\">",
"     21",
"    </a>",
"    ]. Rarely do such infections create acute management problems during flight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     General environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airplanes are noisy and subject passengers to significant vibration, and traveling long distances disrupts circadian rhythms and timing of medicines. Turbulence can precipitate motion sickness, and falling overhead items can cause significant head trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/10\">",
"     10",
"    </a>",
"    ]. Food poisonings can occur during flight, although generally these present after the plane has landed. Prolonged immobility in a sitting position, along with dehydration and hemoconcentration, are risk factors for thromboembolic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     AIRLINE PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each airline follows a different protocol for managing an inflight medical emergency, and each event is handled on an individual basis. A general outline is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Crew and captain are notified of medical emergency,",
"     </li>",
"     <li>",
"      Crew solicits assistance from on-board medical professionals as needed.",
"     </li>",
"     <li>",
"      Captain calls for ground-based medical assistance as needed.",
"     </li>",
"     <li>",
"      Based on assessment of passenger's condition, the captain determines course of action, which may include: request for medical personnel to meet the flight upon arrival, an expedited landing, or diversion to a closer location [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/11,21\">",
"       11,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Under all circumstances, the captain remains the ultimate decision maker for any commercial aircraft. Any medical advice, whether from ground or on-board medical professionals, is exactly that &mdash; advice. In making any decisions, the captain must consider weather conditions, turbulence, air traffic, approach charts, runway length, landing weight of the airplane, and proximity to appropriate ground medical facilities. Even under ideal conditions, the captain and crew require at least 20 minutes to land the aircraft.",
"   </p>",
"   <p>",
"    The role of the volunteer medical professional is to assist the flight crew with the medical problem, not to take control. The clinician may use the resources on board, consult with ground-based medical support personnel, request that the flight crew lower the altitude of the plane to improve the patient's oxygenation, and recommend diversion of the aircraft [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RESOURCES ON BOARD AN AIRCRAFT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Federal Aviation Administration (FAA) requires passenger-carrying aircraft weighing more than 7500 pounds (3400 kilograms) maximum capacity with at least one flight attendant to carry an enhanced emergency medical kit (EMK) with specified contents. This is in addition to a basic first aid kit, which contains bandages, compresses, antiseptic swabs, arm and leg splints, tape and scissors, and ammonia inhalants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2\">",
"     2",
"    </a>",
"    ]. The required EMK contents include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      tablets: 325 mg",
"     </li>",
"     <li>",
"      Antihistamine (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ) tablets: 25 mg",
"     </li>",
"     <li>",
"      Antihistamine (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ), 50 mg injectable single dose",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       Atropine",
"      </a>",
"      : 0.5 mg, single 5 mL",
"     </li>",
"     <li>",
"      Dextrose 50 percent",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      50 mL injectable",
"     </li>",
"     <li>",
"      Epinephrine 1:1,000 (for IM injection)",
"     </li>",
"     <li>",
"      Epinephrine 1:10,000, 2 mL injectable",
"     </li>",
"     <li>",
"      Inhaled bronchodilator (metered dose or equivalent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      : 5 mL, 20",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Nitroglycerine tablets: 0.4 mg",
"     </li>",
"     <li>",
"      Nonnarcotic analgesic",
"     </li>",
"     <li>",
"      Saline solution, 500 mL",
"     </li>",
"     <li>",
"      Instructions for medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Automated external defibrillator",
"     </li>",
"     <li>",
"      Sphygmomanometer",
"     </li>",
"     <li>",
"      Stethoscope",
"     </li>",
"     <li>",
"      Oropharyngeal airways",
"     </li>",
"     <li>",
"      Latex gloves or equivalent",
"     </li>",
"     <li>",
"      Syringes",
"     </li>",
"     <li>",
"      Needles",
"     </li>",
"     <li>",
"      IV administration kit with tubing and connectors",
"     </li>",
"     <li>",
"      Self-inflating manual resuscitation device (AMBU bag) with masks",
"     </li>",
"     <li>",
"      Cardiopulmonary resuscitation (CPR) masks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some US airlines have enhanced EMKs containing additional acute cardiac life support drugs and equipment. The EMK may be opened only when authorized by a physician, either on board or on the ground. The European Joint Aviation Authority and several international carriers have similar requirements for the contents of EMKs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1\">",
"     1",
"    </a>",
"    ]. Medicines carried by passengers provide another resource. A list of EMK medications and equipment recommended by the Air Transport Medicine Committee of the Aerospace Medical Association is provided (",
"    <a class=\"graphic graphic_table graphicRef53375 \" href=\"UTD.htm?11/61/12253\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Automated external defibrillator",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FAA requires all commercial aircraft to carry an automated external defibrillator (AED) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2\">",
"     2",
"    </a>",
"    ]. The vast majority of episodes of sudden cardiac arrest are due to arrhythmias, with ventricular fibrillation (VF) being the most common. VF can be treated effectively with defibrillation, but time is critical [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/31\">",
"     31",
"    </a>",
"    ]. AEDs can be used for cardiac monitoring in addition to defibrillation. In one report of inflight AED use, the device was used in 40 of 169 cases to treat cardiac arrest with the remainder for cardiac monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large prospective observational studies have shown that defibrillation with an AED substantially improves the chances of survival to discharge compared with CPR alone. If a cardiac arrest occurs during flight, at least 20 minutes will pass until defibrillation is possible, unless AEDs are maintained aboard aircraft. One study that examined the use of AEDs in one airline over two years found that AEDs successfully shocked 13 of 14 patients in VF, of whom 40 percent survived to hospital discharge. Another study documented defibrillation in 9 of 10 patients found to be in VF or unstable ventricular tachycardia, of whom 5 survived [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/32\">",
"     32",
"    </a>",
"    ]. The authors extrapolated arrest and resuscitation rates to worldwide air travel and estimated that 452 passengers would have VF arrests inflight and 93 would live (21 percent) because of AED use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/33\">",
"     33",
"    </a>",
"    ]. The epidemiology of sudden cardiac arrest and other aspects of AED allocation and efficacy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=see_link\">",
"     \"Outcome of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link\">",
"     \"Automated external defibrillators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen is available for inflight medical emergencies but often is limited to flow rates between 2 and 4 L per minute. Most air carriers will provide oxygen for a fee to passengers with stable medical conditions who require low-flow oxygen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Crew",
"    </span>",
"    &nbsp;&mdash;&nbsp;All crew members are required to be trained in the location, function, and operation of the enhanced emergency medical equipment. Flight attendants also receive recurrent training in AED usage and are certified in standard CPR and first aid. They may also be trained in their airline's first aid protocols for various emergencies, but they are not required to meet proficiency standards established for emergency medical personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ground-based medical advice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical advice is available in two forms. Many airlines employ physicians who are available by radio or telephone to help with emergencies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. Some airlines contract with a third party that provides physician access [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In both situations, the physicians available have training and experience in aviation medicine, know the resources on board, and can advise either the flight crew or a physician passenger.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COMMON INFLIGHT EMERGENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common serious inflight medical emergencies that lead to diversions result from cardiac, neurologic, and pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1,10,21\">",
"     1,10,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chief cardiac complaint is typically chest pain or angina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=see_link\">",
"     \"Evaluation of chest pain in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .) Cardiac complaints comprise about 20 percent (&plusmn;10) of inflight medical emergencies, and in most studies they are the most common cause of aircraft diversion (about 20 to 46 percent) and passenger death (more than 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/4,6,8,10,15,34,35\">",
"     4,6,8,10,15,34,35",
"    </a>",
"    ]. One study found that of 40 passengers subsequently admitted to an ICU, 27 were for cardiac causes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1,4,15,34,35\">",
"     1,4,15,34,35",
"    </a>",
"    ]. Triggers include the low cabin oxygen pressure, the exertion of travel, and medicine noncompliance due to circadian disruption or lack of access to medications in checked baggage.",
"   </p>",
"   <p>",
"    Diagnostic tools available inflight include a stethoscope, a sphygmomanometer, and an automated external defibrillator (AED), for rhythm determination. Treatment options include an AED, oxygen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , nitrates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , and epinephrine. Enhanced emergency medical kits (EMKs) may include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    is also available in the EMK, although it is no longer considered a first-line drug for treating or preventing acute ventricular arrhythmias in the setting of ischemia, especially if an AED is available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/36\">",
"     36",
"    </a>",
"    ]. Consideration can be given to lowering the plane's altitude in order to increase cabin oxygen pressure and improve oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/10,21\">",
"     10,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complaints, including syncope, seizure, and dizziness, comprise from 15 to 40 percent of inflight emergencies. In most studies, neurologic complaints are the second most common cause for diversion accounting for between 15 and 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1,4,8,15,34,35\">",
"     1,4,8,15,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the case of syncope, the clinician must first consider serious causes, such as a cardiac arrhythmia or ischemia, and cerebrovascular disease. Syncope may be the result of a vasovagal episode, and it can also be precipitated by a myriad of flight-related factors, including prolonged sitting and dehydration due to dry cabin air, limited access to liquids, and alcohol consumption. A careful history, brief physical exam, and an AED to determine the patient's rhythm, can be used to assess the patient. Treatment is generally supportive, eg, laying down the passenger with vasovagal syncope to improve venous return and providing low-flow oxygen to improve unrecognized hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/19\">",
"     19",
"    </a>",
"    ]. Normal saline is available in limited amounts to treat hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=see_link\">",
"     \"Approach to the adult patient with syncope in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific treatment of an inflight seizure is possible on airlines that equip their EMKs with an injectable benzodiazepine, but neither benzodiazepines nor any other sedative or antiepileptic are currently required by the FAA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1\">",
"     1",
"    </a>",
"    ]. Other passengers may be carrying",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , which can be crushed and given as a suppository. Dextrose is available to treat a seizure or altered mental status precipitated by hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Respiratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory events, mainly asthma and COPD exacerbations, are less frequent than either cardiac or neurologic events, comprising about 5 to 10 percent of overall complaints and 5 to 15 percent of diversions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1,4,10,15,34\">",
"     1,4,10,15,34",
"    </a>",
"    ]. Respiratory disease causes the second greatest number of deaths after cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. Possible triggers include the dry cabin air and medicine noncompliance due to the logistics of travel. Available treatments include: oxygen, bronchodilator inhalers either in the EMK or from other passengers, epinephrine, injectable glucocorticoids in some EMKs, and oral and endotracheal airways with bag mask ventilation devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link\">",
"     \"Evaluation of the adult with dyspnea in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain, nausea, vomiting and, less often, diarrhea are commonly reported inflight complaints. Pain, nausea, and vomiting can sometimes be attributed directly to air travel, with the change in barometric pressure, dry air, noise and vibration of the plane, dehydration, and poor diet [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/1,11,21,23\">",
"     1,11,21,23",
"    </a>",
"    ]. The clinician must always first consider a cardiac or other potentially life-threatening cause. Basic gastrointestinal complaints can be treated with anti-emetics from the EMK and antacids from passengers. An antacid may relieve pain from a GI source, but its effectiveness does not rule out a cardiac cause for epigastric pain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Intravenous fluids can also be used in severe cases to treat dehydration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=see_link\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=see_link\">",
"     \"Emergent evaluation of the child with acute abdominal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor allergic reactions are easily treated, but the rare case of anaphylaxis can be more challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/10\">",
"     10",
"    </a>",
"    ]. This can be treated with IM epinephrine and antihistamines, found in the EMK, and IV fluids. Basic airway equipment is also available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diabetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemic episodes in patients with diabetes can occur during air travel. The stress of air travel can easily cause the patient to miss meals or have difficulty coordinating blood glucose monitoring and medication dosages. Hypoglycemic episodes are often mild and can be treated with a source of sugar, for example a snack or juice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/24\">",
"     24",
"    </a>",
"    ]. Severe cases may require IV dextrose provided in the EMK.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Items frequently fall from storage bins during flight, and heavy objects can cause serious injury. A physician can apply basic first aid, immobilize the cervical spine when appropriate, monitor the patient's mental status, and offer advice on the need for diversion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=see_link\">",
"     \"Skull fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link\">",
"     \"Facial trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Behavioral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Violent behavior aboard airplanes has been occurring more frequently, and it is increasingly publicized by the press. One study of American Airlines reported violent incidents tripling between 1994 and 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21\">",
"     21",
"    </a>",
"    ]. A significant increase in social and emotional stress preceding departure has occurred since the events of September 11, 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/23\">",
"     23",
"    </a>",
"    ]. Episodes of \"air rage,\" which are frequently triggered by alcohol or drug use or nicotine withdrawal, involve disruptive violent behavior toward the cabin crew. A physician may help by sedating the passenger with parenteral medicines, if available in the EMK. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LIABILITY AND LEGAL PROTECTION FOR GOOD SAMARITANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fear of liability has been cited as a reason preventing trained medical personnel traveling as passengers from assisting during medical emergencies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21,39\">",
"     21,39",
"    </a>",
"    ]. The exact impact of this fear is unclear. Fifty-two resident and attending physicians in New York City were asked specifically if they would volunteer on an airplane if help were requested by the crew. Not one physician surveyed admitted she would refuse to render care, nor did any cite fear of legal liability as a deterrent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/39\">",
"     39",
"    </a>",
"    ]. Furthermore, a review of air medical emergencies states that no litigation has been brought against a physician providing aid during an inflight emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21\">",
"     21",
"    </a>",
"    ]. Nevertheless, knowledge of Good Samaritan legislation can reassure the physician volunteer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     United States Law",
"    </span>",
"    &nbsp;&mdash;&nbsp;US law does not obligate a physician to render assistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21,40\">",
"     21,40",
"    </a>",
"    ]. It is, however, widely considered an ethical duty to provide help when possible. The Aviation Medical Assistance Act of 1998 applies when a medical professional volunteers to provide care during a medical emergency. The Samaritan is protected against malpractice litigation, if the following conditions are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The Samaritan is medically qualified to perform the service",
"     </li>",
"     <li>",
"      The Samaritan acts voluntarily",
"     </li>",
"     <li>",
"      The Samaritan acts in good faith",
"     </li>",
"     <li>",
"      The Samaritan does not engage in gross negligence or willful misconduct",
"     </li>",
"     <li>",
"      The Samaritan receives no monetary compensation (seat upgrades and travel vouchers do not count as compensation) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21,40,41\">",
"       21,40,41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     International law",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining which country's laws apply on international flights can be a challenge. The laws of the country from which the aircraft departed, toward which it is traveling, or in which its airline is based may all apply. British and Canadian laws are similar to those of the United States discussed above. A major difference is found in countries that regulate air travel under civil law (eg, France and Germany, among many countries in the European Union). They impose an obligation on physicians to render aid; if aid is not provided, the physician can be punished by a fine or imprisonment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Legal guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for avoiding legal complications include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obtain patient consent whenever possible.",
"     </li>",
"     <li>",
"      Use an interpreter if necessary and available.",
"     </li>",
"     <li>",
"      Recommend diversion to the closest appropriate airport for any serious condition.",
"     </li>",
"     <li>",
"      Document the following in writing: history, examination, impression, treatment, and communication with crew and ground medical support.",
"     </li>",
"     <li>",
"      Be cautious with unfamiliar interventions [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7417/abstract/21,40\">",
"       21,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians are increasingly called upon to render aid during inflight medical emergencies. Below is a summary of important facts to assist physician Samaritans:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of inflight medical emergencies is increasing, although the precise incidence is unknown. Cardiac, neurologic, and respiratory complaints comprise the more serious emergencies, as defined by aircraft diversion or use of ground-based medical assistance. Of these, cardiac emergencies are most common. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aircraft cabin is pressurized typically to the equivalent of 5000 to 8000 feet (1500 to 2500 meters) above sea level. In individuals with cardiopulmonary disease, the ability to compensate for this relatively hypoxic environment can be insufficient. For them, a relatively small drop in oxygen saturation may occur on the steep part of the oxyhemoglobin dissociation curve, severely compromising their cardiopulmonary reserves, and precipitating a medical emergency such as cardiac ischemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cabin environment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diminished cabin air pressure during flight can lead to the expansion of gas up to 30 percent compared with sea level. A medical emergency can ensue if the expanding gas is constrained within a confined space such as the pleural cavity (pneumothorax), the middle ear (tympanic membrane rupture), or another body cavity after surgery. Gas expansion can also create problems with inflated medical devices, such as tracheostomy cuffs, gastric feeding tubes, and bladder catheters. The low humidity of cabin air can exacerbate pulmonary problems such as asthma and may predispose some passengers to dehydration. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cabin environment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Each airline has its own medical emergency protocol. Under all circumstances, the captain remains the ultimate decision maker for any commercial aircraft. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Airline protocols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The FAA requires passenger-carrying aircraft weighing more than 7500 pounds (3400 kilograms) maximum capacity with at least one flight attendant to carry an enhanced emergency medical kit (EMK), in addition to a basic first aid kit. The EMK contains specified equipment (eg, automated external defibrillator [AED], stethoscope) and medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , nitrates, epinephrine, bronchodilators, dextrose). Oxygen is available. Ground-based medical support from physicians with expertise in managing inflight medical emergencies is also readily available. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Resources on board an aircraft'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac complaints comprise about 20 percent of inflight medical emergencies, and in most studies are the most common cause of aircraft diversion and passenger death. Chest pain and angina are most common.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      , nitrates, and oxygen are available for treatment. In addition to defibrillation, AEDs can be used to assess a patient's cardiac rhythm. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Common inflight emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Syncope, seizure, and dizziness are the most common neurologic emergencies. Treatment options are limited, and care is generally supportive. Intravenous normal saline and dextrose are available. Some airlines include an injectable benzodiazepine in their EMK. Benzodiazepines may also be obtained from other passengers' personal medications. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Common inflight emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory events, mainly asthma and COPD exacerbations, comprise about 5 to 15 percent of diversions and represent the second greatest number of deaths. Available treatments include: oxygen, bronchodilators either in the EMK or from other passengers, epinephrine, injectable glucocorticoids in some EMKs, and oral and endotracheal airways with bag mask ventilation devices. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Common inflight emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal complaints such as abdominal pain and nausea are common aboard aircraft, but they are rarely medical emergencies. Other emergencies, such as allergic and hypoglycemic reactions can occur. Basic equipment and medications are available for management. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Common inflight emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians who come to the assistance of passengers aboard aircraft are protected from liability in the United States, Canada, and Great Britain by Good Samaritan legislation. According to the laws of France, Germany, and other European nations, physicians are obligated to provide aid when it is requested by the crew. Guidelines to help avoid legal pitfalls are included above. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Liability and legal protection for good samaritans'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95130807\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/1\">",
"      Sirven JI, Claypool DW, Sahs KL, et al. Is there a neurologist on this flight? Neurology 2002; 58:1739.",
"     </a>",
"    </li>",
"    <li>",
"     Medical Guidelines Task Force AMA: Medical guidelines for airline travel, 2nd ed, Aviat Space Environ Med 2003; 74:A1 www.asma.org (Accessed on November 13, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/3\">",
"      DeJohn CA, Wolbrink AM, V&eacute;ronneau SJ, et al. An evaluation of in-flight medical care in the U.S. Aviat Space Environ Med 2002; 73:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/4\">",
"      Delaune EF 3rd, Lucas RH, Illig P. In-flight medical events and aircraft diversions: one airline's experience. Aviat Space Environ Med 2003; 74:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/5\">",
"      Cummins RO, Schubach JA. Frequency and types of medical emergencies among commercial air travelers. JAMA 1989; 261:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/6\">",
"      Lyznicki JM, Williams MA, Deitchman SD, et al. Inflight medical emergencies. Aviat Space Environ Med 2000; 71:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/7\">",
"      Ruskin KJ. In-flight medical emergencies: time for a registry? Crit Care 2009; 13:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/8\">",
"      Chan SB, Hogan TM, Silva JC. Medical emergencies at a major international airport: in-flight symptoms and ground-based follow-up. Aviat Space Environ Med 2002; 73:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/9\">",
"      Speizer C, Rennie CJ 3rd, Breton H. Prevalence of in-flight medical emergencies on commercial airlines. Ann Emerg Med 1989; 18:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/10\">",
"      Dowdall N. \"Is there a doctor on the aircraft?\" Top 10 in-flight medical emergencies. BMJ 2000; 321:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/11\">",
"      Szmajer M, Rodriguez P, Sauval P, et al. Medical assistance during commercial airline flights: analysis of 11 years experience of the Paris Emergency Medical Service (SAMU) between 1989 and 1999. Resuscitation 2001; 50:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/12\">",
"      Weinlich M, Nieuwkamp N, Stueben U, et al. Telemedical assistance for in-flight emergencies on intercontinental commercial aircraft. J Telemed Telecare 2009; 15:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/13\">",
"      Nordenberg L. Dealing with the depths of depression. FDA Consum 1998; 32:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/14\">",
"      Possick SE, Barry M. Evaluation and management of the cardiovascular patient embarking on air travel. Ann Intern Med 2004; 141:148.",
"     </a>",
"    </li>",
"    <li>",
"     DeJohn, C, Veronneau, SJ, Wolbrink, AM. The evaluation of inflight medical care aboard selected US air carriers: 1996-1997. Federal Aviation Administration, Technical report no. DOT/FAA/AM-0013, Office of Aviation Medicine, Washington DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/16\">",
"      Hung KK, Chan EY, Cocks RA, et al. Predictors of flight diversions and deaths for in-flight medical emergencies in commercial aviation. Arch Intern Med 2010; 170:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/17\">",
"      Baltsezak S. Clinic in the air? A retrospective study of medical emergency calls from a major international airline. J Travel Med 2008; 15:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/18\">",
"      Rayman RB. Inflight medical kits. Aviat Space Environ Med 1998; 69:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/19\">",
"      Johnson AO. Chronic obstructive pulmonary disease * 11: fitness to fly with COPD. Thorax 2003; 58:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/20\">",
"      Hampson NB, Kregenow DA, Mahoney AM, et al. Altitude exposures during commercial flight: a reappraisal. Aviat Space Environ Med 2013; 84:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/21\">",
"      Gendreau MA, DeJohn C. Responding to medical events during commercial airline flights. N Engl J Med 2002; 346:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/22\">",
"      Matsumoto K, Goebert D. In-flight psychiatric emergencies. Aviat Space Environ Med 2001; 72:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/23\">",
"      DeHart RL. Health issues of air travel. Annu Rev Public Health 2003; 24:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/24\">",
"      Bettes TN, McKenas DK. Medical advice for commercial air travelers. Am Fam Physician 1999; 60:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/25\">",
"      Wallace TW, Wong T, O'Bichere A, Ellis BW. Managing in flight emergencies. BMJ 1995; 311:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/26\">",
"      Rayman RB. Passenger safety, health, and comfort: a review. Aviat Space Environ Med 1997; 68:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/27\">",
"      Hsueh PR, Chen PJ, Hsiao CH, et al. Patient data, early SARS epidemic, Taiwan. Emerg Infect Dis 2004; 10:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/28\">",
"      Kenyon TA, Valway SE, Ihle WW, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight. N Engl J Med 1996; 334:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/29\">",
"      Olsen SJ, Chang HL, Cheung TY, et al. Transmission of the severe acute respiratory syndrome on aircraft. N Engl J Med 2003; 349:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/30\">",
"      Thibeault C, Evans A, Air Transport Medicine Committee, Aerospace Medical Association. Emergency medical kit for commercial airlines: an update. Aviat Space Environ Med 2007; 78:1170.",
"     </a>",
"    </li>",
"    <li>",
"     American Heart Association. Heart Disease and Stroke Statistics-2002 Update, Dallas, TX 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/32\">",
"      Brown AM, Rittenberger JC, Ammon CM, et al. In-flight automated external defibrillator use and consultation patterns. Prehosp Emerg Care 2010; 14:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/33\">",
"      Page RL, Joglar JA, Kowal RC, et al. Use of automated external defibrillators by a U.S. airline. N Engl J Med 2000; 343:1210.",
"     </a>",
"    </li>",
"    <li>",
"     DeJohn, C, Veronneau, SJ, Hordinsky, JR. Inflight medical care: an update. Report number DOT/FAA/AM-97/2, FAA Office of Aerospace Medicine; Washingon, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/35\">",
"      Hordinsky JR, George MH. Response capability during civil air carrier inflight medical emergencies. Aviat Space Environ Med 1989; 60:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/36\">",
"      Hallstrom AP, Ornato JP, Weisfeldt M, et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med 2004; 351:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/37\">",
"      Wrenn K, Slovis CM, Gongaware J. Using the \"GI cocktail\": a descriptive study. Ann Emerg Med 1995; 26:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/38\">",
"      Berman DA, Porter RS, Graber M. The GI Cocktail is no more effective than plain liquid antacid: a randomized, double blind clinical trial. J Emerg Med 2003; 25:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/39\">",
"      Gross CP, Reisman AB, Schwartz MD. The physician as ambivalent Samaritan: will internists resuscitate victims of out-of-hospital emergencies? J Gen Intern Med 1998; 13:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/40\">",
"      Newson-Smith MS. Passenger doctors in civil airliners--obligations, duties and standards of care. Aviat Space Environ Med 1997; 68:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7417/abstract/41\">",
"      Dachs R. Responding to an in-flight emergency. Am Fam Physician 2003; 68:975.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 185 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7417=[""].join("\n");
var outline_f7_15_7417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CABIN ENVIRONMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reduced oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Air pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Air quality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Transmission of airborne pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      General environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AIRLINE PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RESOURCES ON BOARD AN AIRCRAFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Automated external defibrillator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Crew",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ground-based medical advice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COMMON INFLIGHT EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Respiratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diabetic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Head injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Behavioral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LIABILITY AND LEGAL PROTECTION FOR GOOD SAMARITANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      United States Law",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      International law",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Legal guidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95130807\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/185\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/185|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/61/12253\" title=\"table 1\">",
"      Emergency medical kit for airlines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=related_link\">",
"      Approach to the adult patient with syncope in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=related_link\">",
"      Automated external defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=related_link\">",
"      Emergent evaluation of the child with acute abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=related_link\">",
"      Evaluation of chest pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=related_link\">",
"      Evaluation of the adult with abdominal pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=related_link\">",
"      Evaluation of the adult with dyspnea in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=related_link\">",
"      Facial trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=related_link\">",
"      Patient assessment for air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35271?source=related_link\">",
"      Pneumothorax and air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=related_link\">",
"      Skull fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_15_7418="Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)";
var content_f7_15_7418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7418/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7418/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7418/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7418/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7418/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/15/7418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/15/7418/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/15/7418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1378183\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of low molecular weight subunits of a variety of normal serum proteins. These fibrils have a predominantly antiparallel &szlig;-pleated sheet configuration (noted on x-ray diffraction), and can be identified on biopsy specimens both by their characteristic appearance on electron microscopy, and by their ability to bind Congo red (leading to green birefringence under polarized light) and thioflavine T (producing an intense yellow-green fluorescence).",
"   </p>",
"   <p>",
"    More than 20 distinct low molecular weight proteins are recognized to form amyloid fibrils. The two most common causes of systemic amyloid deposition are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunoglobulin light chain (AL) amyloidosis (previously referred to as primary amyloidosis) in which the fibrils are composed of fragments of monoclonal light chains. Affected patients may have amyloidosis alone or in association with other plasma cell dyscrasias (multiple myeloma, Waldenstrom macroglobulinemia). All forms of systemic amyloidosis in which the fibrils are derived from monoclonal light chains, regardless of the nature of the underlying plasma cell disorder (eg, MGUS, multiple myeloma, or Waldenstrom macroglobulinemia) are considered AL amyloidosis.",
"     </li>",
"     <li>",
"      AA amyloidosis in which the fibrils are composed of fragments of the acute phase reactant serum amyloid A. AA amyloidosis is typically reactive (secondary) to chronic inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"       \"Pathogenesis of secondary (AA) amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AL amyloidosis is a systemic disorder that can present with a variety of symptoms or signs, including heavy proteinuria (usually in the nephrotic range), edema, hepatosplenomegaly, otherwise unexplained heart failure, and the carpal tunnel syndrome. Although virtually all patients have multisystem amyloid deposition, it is not uncommon to present with evidence of mainly one organ being affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=see_link\">",
"     \"Gastrointestinal amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and differential diagnosis of AL amyloidosis will be discussed here. An overview of the amyloid disorders as well as the pathogenesis, prognosis, and treatment of AL amyloidosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143697\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AL amyloidosis is an uncommon disorder and the exact incidence is unknown. In the United States, the incidence appears to be stable at approximately 6 to 10 cases per million person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AL amyloidosis is a disease of older adults. As with other plasma cell dyscrasias, the age-specific incidence rates increase in each decade of life after age 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/1\">",
"     1",
"    </a>",
"    ]. The median age at diagnosis is 64 years and less than 5 percent of patients are under the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. There is a male predominance with men accounting for 65 to 70 percent of patients.",
"   </p>",
"   <p>",
"    AL amyloidosis occurs in all races and all geographic locations; however, there are little data regarding whether the incidence varies by ethnicity or geography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Relation to other plasma cell disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who ultimately show clinical evidence of AL amyloidosis present with monoclonal gammopathy of undetermined significance (MGUS). Over time, a small number of patients with MGUS eventually develop symptoms or signs related to AL amyloidosis, multiple myeloma, or Waldenstr&ouml;m macroglobulinemia (WM), at a rate of approximately 1 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H22391006#H22391006\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Disease progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AL amyloidosis can also occur in patients with other plasma cell dyscrasias, including multiple myeloma and WM, malignant disorders of plasma cells or lymphoplasmacytic cells, respectively.",
"   </p>",
"   <p>",
"    When multiple myeloma and AL amyloidosis are diagnosed in the same patient, the myeloma is typically diagnosed before or around the time of the amyloid diagnosis. Less commonly, myeloma develops more than six months after the diagnosis of amyloid (delayed progression):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 1596 patients with AL amyloidosis seen at the Mayo Clinic between 1960 and 1994, only six (0.4 percent) showed delayed progression (at 10 to 81 months) to overt myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/6\">",
"       6",
"      </a>",
"      ]. This usually occurred in patients without cardiac or hepatic amyloid who lived long enough to develop myeloma.",
"     </li>",
"     <li>",
"      In a series of 4319 patients seen at the Mayo Clinic between 1990 and 2008 with a diagnosis of myeloma who had at least six months of follow-up, there were 47 patients (1.1 percent) in whom the diagnosis of AL amyloidosis followed the diagnosis of myeloma by at least six months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/7\">",
"       7",
"      </a>",
"      ]. Outcome of these patients was poor, especially in those with cardiac involvement, with a median survival after the diagnosis of AL amyloidosis of nine months (95% CI 4-14 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding of 30 percent or more plasma cells, hypercalcemia, bone pain, or lytic bone lesions in a patient with AL amyloidosis is suggestive of the combination of myeloma and amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143177\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1664672\">",
"    <span class=\"h2\">",
"     Systemic presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation in AL amyloidosis depends on the number and nature of the organs affected. In some patients only one organ is affected, while in others there is extensive multi-system involvement. However, even in patients with more than one organ affected, it is usually possible to identify one organ as the \"dominant\" site of involvement. A more complete overview of the clinical manifestations of amyloidosis in general can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H10#H10\">",
"     \"An overview of amyloidosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-specific systemic symptoms, including fatigue and unintentional weight loss, are common in patients with AL amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/3\">",
"     3",
"    </a>",
"    ]. Other common clinical presentations of AL amyloidosis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nephrotic syndrome",
"      </strong>",
"      &mdash; Renal involvement occurs in approximately 70 percent of patients and most often presents as asymptomatic proteinuria or clinically apparent nephrotic syndrome (50 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"       \"Renal amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Restrictive cardiomyopathy",
"      </strong>",
"      &mdash; Cardiac involvement is seen in approximately 60 percent of patients and is typically characterized by thickening of the interventricular septum and ventricular wall (",
"      <a class=\"graphic graphic_movie graphicRef64330 \" href=\"UTD.htm?43/47/44787\">",
"       movie 1",
"      </a>",
"      ). This can lead to systolic or diastolic dysfunction and the symptoms of heart failure. Other manifestations that can occur include sudden death or syncope due to arrhythmia or heart block, and rarely angina or infarction due to accumulation of amyloid in the coronary arteries. Elevations in serum brain natriuretic peptide (BNP) in patients with AL amyloidosis are seen before the onset of clinical heart failure and are a marker of cardiac involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Peripheral neuropathy",
"      </strong>",
"      &mdash; Mixed sensory and motor peripheral neuropathy (20 percent)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      autonomic neuropathy (15 percent) is a prominent feature in AL amyloidosis. Symptoms of numbness, paresthesia, and pain are frequently noted, as in peripheral neuropathy of many other causes. Compression of peripheral nerves, especially the median nerve within the carpal tunnel, can cause more localized sensory changes. Symptoms of bowel or bladder dysfunction and findings of orthostatic hypotension may be due to autonomic nervous system damage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link&amp;anchor=H5#H5\">",
"       \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Association with plasma cell dyscrasias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hepatomegaly, with elevated liver enzyme levels",
"      </strong>",
"      &mdash; Hepatomegaly with or without splenomegaly is seen in as many as 70 percent of patients. A cholestatic pattern with elevated liver enzymes is seen in approximately 25 percent. Gastrointestinal involvement appears to be less common than in other forms of amyloidosis, with biopsy diagnosed disease and clinically apparent disease occurring in only 8 and 1 percent, respectively, of 769 patients in a retrospective review from the Mayo Clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/9\">",
"       9",
"      </a>",
"      ]. Potential gastrointestinal manifestations include bleeding (due to vascular fragility and loss of vasomotor responses to injury), gastroparesis, constipation, bacterial overgrowth, malabsorption, and intestinal pseudo-obstruction resulting from dysmotility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=see_link\">",
"       \"Gastrointestinal amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Macroglossia and involvement of other muscles",
"      </strong>",
"      &mdash; Amyloid infiltration of skeletal muscles may cause visible enlargement (ie, pseudohypertrophy). A large tongue (ie, macroglossia), or lateral scalloping of the tongue from impingement on the teeth, is characteristic of AL amyloid (",
"      <a class=\"graphic graphic_picture graphicRef79126 \" href=\"UTD.htm?2/48/2819\">",
"       picture 1",
"      </a>",
"      ). Arthropathy may be due to amyloid deposition in joints and surrounding structures. The \"shoulder pad\" sign is visible enlargement of the anterior shoulder due to fluid in the glenohumeral joint",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      amyloid infiltration of the synovial membrane and surrounding structures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11623?source=see_link&amp;anchor=H3#H3\">",
"       \"Musculoskeletal manifestations of amyloidosis\", section on 'Muscle involvement in AL amyloid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Purpura and other skin manifestations",
"      </strong>",
"      &mdash; Purpura, characteristically elicited in a periorbital distribution (raccoon eyes) by a valsalva maneuver or minor trauma, is present in only a minority of patients, but is highly characteristic of AL amyloidosis (",
"      <a class=\"graphic graphic_picture graphicRef51684 \" href=\"UTD.htm?10/46/10979\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/10\">",
"       10",
"      </a>",
"      ]. Other signs of skin involvement include waxy thickening, easy bruising (ecchymoses) (",
"      <a class=\"graphic graphic_picture graphicRef69541 \" href=\"UTD.htm?12/43/12982\">",
"       picture 3",
"      </a>",
"      ), and subcutaneous nodules or plaques. Infiltration of the subcutaneous fat is generally asymptomatic but provides a convenient site for biopsy.",
"     </li>",
"     <li>",
"      <strong>",
"       Bleeding diathesis",
"      </strong>",
"      &mdash; Amyloidosis may be directly associated with a bleeding diathesis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. In one report of 337 patients, abnormal bleeding and abnormal coagulation tests were seen in 28 and 51 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/12\">",
"       12",
"      </a>",
"      ]. Proposed mechanisms include factor X deficiency due to binding to amyloid fibrils primarily in the liver and spleen; decreased synthesis of coagulation factors in patients with advanced liver disease; and acquired von Willebrand disease. However, some patients with abnormal bleeding have no abnormality in any coagulation test [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/11\">",
"       11",
"      </a>",
"      ]. In such patients, amyloid infiltration of blood vessels may contribute to the bleeding diathesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"       \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 10 percent of patients have coexisting multiple myeloma characterized by &gt;30 percent plasma cells on bone marrow examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lytic bone lesions. Such patients may present with signs and symptoms related to the multiple myeloma, such as anemia, bone pain, hypercalcemia, and infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1664740\">",
"    <span class=\"h2\">",
"     IgM-associated AL amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;AL amyloidosis is an uncommon complication of IgM-associated monoclonal gammopathies, such as Waldenstrom macroglobulinemia (WM) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. In a retrospective French study of 64 patients with IgM-associated systemic AL amyloidosis, prior conditions included WM (78 percent), IgM MGUS (14 percent), and non-Hodgkin lymphoma (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/16\">",
"     16",
"    </a>",
"    ]. The involved light chain was kappa in 59 percent of the French cases and 46 percent of a second series of 103 patients from the United Kingdom (UK) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link&amp;anchor=H28#H28\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Amyloidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the French series, the most commonly involved organs were the kidney (55 percent), soft tissue (53 percent), and heart (36 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/16\">",
"       16",
"      </a>",
"      ]. When compared with 99 patients with non-IgM systemic AL [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/18\">",
"       18",
"      </a>",
"      ], involvement of the lymph nodes (31 versus 3 percent) and lung (17 versus 2 percent) was significantly more common in those with IgM-related AL amyloidosis. On multivariate analysis, adverse prognostic features included albumin &lt;3.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (hazard ratio 2.5; 95% CI 1.7-3.7) and cardiac involvement (hazard ratio 3.3; 95% CI 2.2-5).",
"     </li>",
"     <li>",
"      In the UK series, the median IgM paraprotein level was 800",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and the serum free light chain ratio was abnormal in 88 percent of those tested [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7747821\">",
"    <span class=\"h2\">",
"     IgD-associated AL amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is extremely rare for patients with AL amyloidosis to have a monoclonal immunoglobulin D (IgD) at the time of diagnosis. The largest single center retrospective case series of 3955 patients with Ig light chain amyloidosis identified 53 patients (1.3 percent) with a serum IgD monoclonal protein [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/19\">",
"     19",
"    </a>",
"    ]. When compared with non-IgD AL amyloid, patients appeared to have a lower frequency of renal and cardiac involvement. At the time of presentation, the most common signs and symptoms were fatigue (60 percent), lower extremity edema (43 percent), paresthesias (32 percent), weight loss (32 percent), dyspnea on exertion (28 percent), and carpal tunnel syndrome (26 percent). Survival appeared similar to that of non-IgD AL amyloid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1664856\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1665772\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1666048\">",
"    <span class=\"h3\">",
"     Choosing a biopsy site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Demonstration of amyloid fibrils upon histologic evaluation of an affected organ (eg, kidney, liver) or a surrogate site (eg, abdominal fat pad, bone marrow) is required for the diagnosis of AL amyloidosis. The choice of the initial biopsy site must take into consideration the expected yield, accessibility of the site, and the risks associated with the procedure.",
"   </p>",
"   <p>",
"    Kidney or liver biopsy is positive in over 90 percent of cases; however, a high success rate can also be achieved by less invasive procedures, such as abdominal fat pad aspirate (60 to 80 percent), rectal biopsy (50 to 70 percent), bone marrow biopsy (50 to 55 percent), or skin (50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/2,20-22\">",
"     2,20-22",
"    </a>",
"    ]. Because of ease, convenience, and high yield, abdominal fat pad aspirate and bone marrow biopsy are the preferred sites to biopsy in patients with suspected AL amyloidosis. Either or both are positive in 90 percent of patients with AL amyloidosis. If AL amyloidosis is still suspected in the setting of negative fat pad aspirate and bone marrow biopsy, then the affected organ should be biopsied.",
"   </p>",
"   <p>",
"    We do not perform gingival biopsy because it is uncomfortable for the patient, and skin biopsies are generally negative unless there is clinical involvement. In addition, some patients have a bleeding diathesis (eg, acquired factor X deficiency), which may limit the safety of biopsy of major internal organs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H16#H16\">",
"     \"An overview of amyloidosis\", section on 'Hematologic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1666055\">",
"    <span class=\"h3\">",
"     Identifying amyloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;On hematoxylin and eosin stained biopsy sections, amyloid appears as a pink, amorphous, waxy substance with a characteristic &lsquo;cracking&rsquo; artifact (",
"    <a class=\"graphic graphic_picture graphicRef63840 \" href=\"UTD.htm?32/25/33177\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/23\">",
"     23",
"    </a>",
"    ]. The presence of amyloid fibrils can be confirmed by their characteristic appearance on electron microscopy (",
"    <a class=\"graphic graphic_picture graphicRef54148 \" href=\"UTD.htm?21/58/22441\">",
"     picture 5",
"    </a>",
"    ) and by their ability to bind Congo red (leading to green birefringence under polarized light) (",
"    <a class=\"graphic graphic_picture graphicRef78183 \" href=\"UTD.htm?37/17/38162\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56789 \" href=\"UTD.htm?32/53/33620\">",
"     picture 7",
"    </a>",
"    ) or thioflavine-T (producing an intense yellow-green fluorescence) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/24\">",
"     24",
"    </a>",
"    ]. Of importance, biopsy sections that are very thin (ie, 6 microns or less) may not stain appropriately with Congo Red despite the presence of amyloid fibrils on electron microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1666063\">",
"    <span class=\"h3\">",
"     Determining the type of amyloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the histologic diagnosis of amyloidosis is made (typically based on the Congo red stain), there are a number of laboratory and histologic findings that are helpful in distinguishing AL amyloidosis from other forms of amyloidosis on tissue specimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunohistochemical staining (eg, for kappa and lambda light chains, transthyretin, and serum amyloid A component) can determine the type of amyloidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/25\">",
"       25",
"      </a>",
"      ]. Positive staining for kappa or lambda indicates AL amyloidosis; positive staining for transthyretin indicates familial or senile (ATTR) amyloidosis; positive staining for serum amyloid A component occurs with secondary (AA) amyloidosis. However, a monoclonal plasma cell staining pattern typical of AL amyloidosis may be missed if the clone is small and masked by normal polyclonal plasma cells [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunofluorescence microscopy in the kidney or other affected tissue (",
"      <a class=\"graphic graphic_picture graphicRef79371 \" href=\"UTD.htm?16/38/16998\">",
"       picture 8",
"      </a>",
"      ) may show deposition of a monoclonal (lambda or kappa) light chain in AL amyloidosis, although some have reported a low sensitivity with renal biopsies (65 percent in one series) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/26\">",
"       26",
"      </a>",
"      ]. Immunofluorescence using light-chain specific antisera and other specialized techniques can also be used with other tissue specimens to help diagnose AL amyloidosis (",
"      <a class=\"graphic graphic_picture graphicRef73654 \" href=\"UTD.htm?20/22/20834\">",
"       picture 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Amino acid sequence analysis of purified amyloid fibrils allows for the characterization of the amyloid protein and exact typing but is cumbersome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laser microdissection with mass spectrometry combines tissue sampling by laser microdissection along with tandem mass spectrometry-based proteomic analysis. In a study of 50 cases of amyloidosis well-characterized by gold standard clinicopathologic criteria (training set) and an independent validation set comprising 41 cases of cardiac amyloidosis, this technique identified the amyloid type with 100 percent specificity and sensitivity in the training set and 98 percent in validation set [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/30-33\">",
"       30-33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the risk of false positives (and negatives) with immunohistochemistry and immunofluorescence, the type of amyloid present is best established by mass spectrometry. However, this test is not widely available, and appropriate tissue samples may need to be sent to referral centers for such testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1666444\">",
"    <span class=\"h3\">",
"     Chromosomal changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AL amyloidosis frequently have chromosomal abnormalities, but there is no single chromosomal change that is diagnostic of this disease. The monotypic plasma cell population in the bone marrow has elements of a neoplastic nature as shown by the frequent finding of numerical chromosomal abnormalities. In a study of bone marrow samples with FISH from 21 patients with AL amyloid, monosomy of chromosome 18 was the most common abnormality, occurring in 72 percent of cases, but trisomy of a variety of chromosomes was also common [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/34\">",
"     34",
"    </a>",
"    ]. Similar prevalences were found in 19 patients with monoclonal gammopathy of undetermined significance (MGUS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chromosomal abnormalities reported with moderate to high frequency in patients with AL amyloidosis include t(11;14)(q13;q32), a translocation frequently seen in multiple myeloma and MGUS; del(13q14), an abnormality associated with a poor prognosis in multiple myeloma; and gain of 1q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathobiology of multiple myeloma\", section on 'Cytogenetic abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Cytogenetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1665099\">",
"    <span class=\"h2\">",
"     Evidence of monoclonal plasma cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of AL amyloidosis requires evidence of a monoclonal plasma cell proliferative disorder as displayed by the presence of a serum or urine monoclonal (M) protein, an abnormal serum free light chain ratio, or clonal plasma cells in the bone marrow.",
"   </p>",
"   <p>",
"    A monoclonal plasma cell proliferative disorder can be assumed if a monoclonal (M) protein is detected in the serum or urine. The monoclonal protein in AL amyloidosis is IgG in approximately 35 percent, IgA in 10 percent, IgM in 5 percent, IgD in 1 percent, and light chain (lambda or kappa) in the remaining patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/39\">",
"     39",
"    </a>",
"    ]. Most patients with AL amyloidosis have little or no intact monoclonal immunoglobulin, but are characterized by the presence of monoclonal free light chain. The monoclonal light chain type is lambda in approximately 70 percent of cases, kappa in 25 percent, and biclonal in 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/40\">",
"     40",
"    </a>",
"    ]. Evaluation with serum and urine immunofixation plus a serum free light chain ratio analysis provides the most sensitive measure for this M protein:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum protein electrophoresis (SPEP), which detects intact monoclonal immunoglobulin, will demonstrate a localized band or peak in less than 50 percent of patients with AL amyloidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H8#H8\">",
"       \"Recognition of monoclonal proteins\", section on 'Serum protein electrophoresis (SPEP)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunofixation techniques designed to identify light chains will detect a serum or urinary monoclonal protein in nearly 90 percent of cases of AL amyloidosis. Of importance, a subset of patients has very small monoclonal protein levels that may only be detected by immunofixation (eg, monoclonal IgD) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H16#H16\">",
"       \"Recognition of monoclonal proteins\", section on 'Serum immunofixation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When serum and urine immunofixation is combined with serum free light chain ratio analysis, a monoclonal protein can be detected in virtually all cases [",
"      <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H2212928#H2212928\">",
"       \"Recognition of monoclonal proteins\", section on 'Serum free light chains'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clonal plasma cells can also be identified in the bone marrow. Bone marrow biopsy specimens typically demonstrate a slightly increased percentage of plasma cells that may appear morphologically normal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/23\">",
"     23",
"    </a>",
"    ]. Less commonly, the bone marrow demonstrates overt myeloma or lymphoplasmacytic lymphoma. A clonal excess of plasma cells (lambda or kappa) can also be demonstrated by immunoperoxidase staining or flow cytometric analysis of specimens of involved bone marrow (",
"    <a class=\"graphic graphic_picture graphicRef79371 \" href=\"UTD.htm?16/38/16998\">",
"     picture 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/41\">",
"     41",
"    </a>",
"    ]. However, a monoclonal plasma cell staining pattern typical of AL amyloidosis may be missed if the clone is small and masked by normal polyclonal plasma cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1666806\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1666860\">",
"    <span class=\"h2\">",
"     Serum amyloid P component scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum amyloid P component (SAP) scintigraphy is a method of measuring the extent of amyloid involvement by using a radiolabeled variant of the SAP found in all amyloid deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Tissue amyloidosis deposits are identified by scintigraphy following the intravenous injection of technetium-labeled SAP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. This test is more accurate in secondary amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/46\">",
"     46",
"    </a>",
"    ] and may be positive even when tissue biopsy has been negative [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of SAP scintigraphy is limited because it is inconvenient, costly, not widely available, and is less helpful in detecting cardiac amyloid. Another limitation is that the SAP is currently obtained from blood donors, thereby carrying a potential infectious risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;AL amyloidosis is suspected in a patient presenting with any one of the following: non-diabetic nephrotic range proteinuria, restrictive cardiomyopathy or otherwise unexplained congestive heart failure, increased NT-proBNP in the absence of primary heart disease, unexplained edema, hepatosplenomegaly, carpal tunnel syndrome, unexplained facial or neck purpura, or macroglossia.",
"   </p>",
"   <p>",
"    The initial evaluation of a patient suspected of having AL amyloidosis should consist of serum and urine immunofixation, serum free light chain ratio analysis, and an abdominal fat pad aspirate and bone marrow biopsy. If AL amyloidosis is still suspected in the setting of negative fat pad aspirate and bone marrow biopsy, then the affected organ (eg, kidney, liver) should be biopsied. (See",
"    <a class=\"local\" href=\"#H1666048\">",
"     'Choosing a biopsy site'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some patients have a bleeding diathesis, which may limit the safety of biopsy of major internal organs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H16#H16\">",
"     \"An overview of amyloidosis\", section on 'Hematologic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for AL amyloidosis have been developed by the Mayo Clinic and the International Myeloma Working Group and require the presence of",
"    <strong>",
"     all",
"    </strong>",
"    of the following four criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence of an amyloid-related systemic syndrome (eg, renal, liver, heart, gastrointestinal tract or peripheral nerve involvement). In order to be included as diagnostic criterion, the organ damage must be felt to be related to amyloid deposition and not to another common disease, such as diabetes or hypertension.(See",
"      <a class=\"local\" href=\"#H1664672\">",
"       'Systemic presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Positive amyloid staining by Congo red in any tissue (eg, fat aspirate, bone marrow or organ biopsy) or the presence of amyloid fibrils on electron microscopy. (See",
"      <a class=\"local\" href=\"#H1666055\">",
"       'Identifying amyloid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence that the amyloid is light chain-related established by direct examination of the amyloid (eg, using mass spectrometry based proteomic analysis; note that immunohistochemistry results to type amyloid may be unreliable). (See",
"      <a class=\"local\" href=\"#H1666063\">",
"       'Determining the type of amyloid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence of a monoclonal plasma cell proliferative disorder (eg, presence of a serum or urine M protein, abnormal serum free light chain ratio, or clonal plasma cells in the bone marrow). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H2212928#H2212928\">",
"       \"Recognition of monoclonal proteins\", section on 'Serum free light chains'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that approximately 2 to 3 percent of patients with AL amyloidosis will",
"    <strong>",
"     not",
"    </strong>",
"    meet the requirement for evidence of a monoclonal plasma cell disorder listed above; the diagnosis of AL amyloidosis must be made with caution in these patients.",
"   </p>",
"   <p>",
"    Given the common occurrence of monoclonal gammopathy of undetermined significance (MGUS) in the general population, especially in the elderly, the presence of a monoclonal protein in conjunction with the demonstration of amyloid deposition may not always indicate that the amyloidosis is of the AL type. As an example, a patient may have senile amyloidosis caused by deposition of transthyretin and a concomitant unrelated MGUS, which can be potentially misdiagnosed as AL amyloidosis. As such, the amyloid itself should be examined directly for light chains rather than assuming a diagnosis of AL amyloidosis based upon the presence of monoclonal light chains in the serum of a patient with amyloid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AL amyloidosis should be distinguished from other forms of amyloidosis, from localized amyloidosis, and from other types of monoclonal immunoglobulin deposition diseases because the clinical course and therapy are markedly different.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58766172\">",
"    <span class=\"h2\">",
"     Other forms of amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other forms of amyloidosis include AA amyloidosis, familial amyloidosis, and senile amyloidosis. All of these entities will demonstrate staining with Congo red (a characteristic of amyloid), but direct examination of the amyloid material will not reveal immunoglobulin light chains (as seen in AL amyloidosis). A diagnosis of AL amyloidosis cannot be assumed based upon the presence of monoclonal light chains in the serum of a patient with amyloid since it is not uncommon for a patient with another form of amyloid to have a concomitant and unrelated monoclonal gammopathy of undetermined significance (MGUS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58766209\">",
"    <span class=\"h3\">",
"     AA amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;AA amyloidosis (previously referred to as secondary amyloidosis) occurs as a complication of a variety of chronic inflammatory conditions, such as rheumatoid arthritis and its variants, bronchiectasis, Crohn's disease and other inflammatory bowel diseases, osteomyelitis, and familial Mediterranean fever. Inflammation leads to increased hepatic production of the acute phase reactant serum amyloid A, which is then degraded in circulating macrophages into smaller amyloid A fragments that are then deposited as fibrils in the tissues. A distinction between AA amyloidosis and AL amyloidosis can be made based upon the identification of immunoglobulin light chains upon the direct examination of the amyloid material in AL amyloid, a feature that is not seen in secondary amyloid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=see_link\">",
"     \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58766300\">",
"    <span class=\"h3\">",
"     Hereditary (familial) amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heritable, autosomal dominant amyloidosis results from mutations in genes coding for several different proteins. The most common &ldquo;amyloidogenic proteins&rdquo; implicated in hereditary amyloidosis are mutated forms of transthyretin (TTR), the alpha chain of fibrinogen A, apolipoprotein AI and AII, lysozyme, and gelsolin. Sporadic cases of hereditary amyloidosis may be confused with AL amyloidosis, and diagnosis requires careful assessment to determine the chemical nature of the amyloid deposits by mass spectroscopy. The frequency with which this might occur was illustrated in a study of 350 patients suspected of having AL amyloidosis by clinical and laboratory findings and the absence of a family history; 34 (9.7 percent) had a mutant gene for an \"amyloidogenic\" protein, most often involving the alpha chain of fibrinogen A or transthyretin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/49\">",
"     49",
"    </a>",
"    ]. The presence of low concentrations of monoclonal immunoglobulins (less than 0.2",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    in eight of these 34 patients may have contributed to the misdiagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link\">",
"     \"Genetic factors in the amyloid diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thorough family history and exclusion of these heritable disorders is important, since the treatment used in AL amyloidosis (eg, chemotherapy, hematopoietic cell transplantation) has no role in the treatment of the hereditary amyloidoses, and is dangerous. Unlike AL amyloidosis, direct examination of the amyloid material in hereditary amyloidosis does not reveal immunoglobulin light chains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H20#H20\">",
"     \"An overview of amyloidosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58766389\">",
"    <span class=\"h3\">",
"     Senile amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis due to deposition of transthyretin (TTR), also referred to as ATTR amyloidosis, can be hereditary (mutated TTR) or senile (unmutated, wild-type TTR). Thus, TTR is an inherently amyloidogenic protein, which forms amyloid late in life in the absence of mutations (senile), whereas certain mutations in the TTR gene result in the formation of a mutant TTR protein that causes amyloidosis earlier in life (hereditary). Age-related (senile) systemic amyloidosis (SSA) refers to the deposition of otherwise normal (wild-type) transthyretin (TTR) in the myocardium and other sites of elderly individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Patients may present with heart failure or an arrhythmia. Recognition is important because survival is better than with AL amyloidosis, and chemotherapy or stem cell transplantation are contraindicated. Unlike AL amyloidosis, direct examination of the amyloid material in senile amyloidosis does not reveal immunoglobulin light chains, but rather reveals TTR deposits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H8#H8\">",
"     \"An overview of amyloidosis\", section on 'Age-related (senile) systemic amyloidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of AL amyloidosis cannot be assumed based upon the presence of monoclonal light chains in the serum of a patient with amyloid since it is not uncommon for a patient with senile amyloid to have a concomitant and unrelated monoclonal gammopathy of undetermined significance (MGUS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58766423\">",
"    <span class=\"h2\">",
"     Other forms of monoclonal immunoglobulin deposition disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monoclonal immunoglobulin deposition diseases (MIDD) are a group of disorders characterized by the accumulation of intact or fragmented abnormal immunoglobulin in visceral and soft tissues resulting in organ damage. The MIDD are plasma cell dyscrasias with abnormal immunoglobulin components secreted by plasma cells or a lymphoplasmacytic neoplasm. There are four major groups of MIDD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AL amyloidosis",
"     </li>",
"     <li>",
"      Light chain deposition disease",
"     </li>",
"     <li>",
"      Light and heavy chain deposition disease",
"     </li>",
"     <li>",
"      Heavy chain deposition disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these entities will have evidence of a monoclonal plasma cell proliferative disorder and many will demonstrate light chains in the serum. However, only AL amyloidosis will demonstrate staining with Congo red.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1662053\">",
"    <span class=\"h3\">",
"     Light chain deposition disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light chain deposition disease (LCDD) is a monoclonal immunoglobulin deposition disease related to AL amyloidosis in which fibril formation does not occur, but fragments of monoclonal light chains are deposited in the tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/2,24\">",
"     2,24",
"    </a>",
"    ]. LCDD typically presents as nephrotic syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/52\">",
"     52",
"    </a>",
"    ]. Most patients with renal involvement progress to end stage renal disease requiring dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/53\">",
"     53",
"    </a>",
"    ]. Less frequently, liver involvement can occur with hepatomegaly and liver dysfunction, either alone or in combination with renal involvement. Rarely, LCDD may involve the heart and lead to cardiomyopathy and heart failure. Patients may progress to overt multiple myeloma; some patients may have coexisting multiple myeloma at initial diagnosis. Unlike AL amyloidosis, LCDD does not stain with Congo red. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link&amp;anchor=H22#H22\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\", section on 'Treatment of LCDD or HCDD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1662108\">",
"    <span class=\"h3\">",
"     Heavy chain deposition disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy chain deposition disease (HCDD) is a rare monoclonal immunoglobulin deposition disease that has clinical characteristics that are similar to AL amyloidosis and light chain deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/52\">",
"     52",
"    </a>",
"    ]. Deposits in HCDD are heavy chains or short (truncated) heavy chains, granular, and do not stain positive with Congo red. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12470?source=see_link\">",
"     \"The heavy chain diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\", section on 'General discussion and definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58766528\">",
"    <span class=\"h2\">",
"     Localized amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized amyloidosis is the term used for local amyloid deposits in tissues such as the tracheobronchial tree, urinary tract, or skin; these deposits are derived from monoclonal light chains, but are not due to an underlying systemic clonal plasma cell disorder. Patients with localized amyloidosis do not develop systemic disease and do not require chemotherapy. Localized amyloidosis is most commonly found in the upper respiratory tract (nasopharynx), urinary bladder, colon, skin and nails, and orbit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. In most of these patients, monoclonal immunoglobulins cannot be found in serum or urine, although the amyloid fibrils are usually light chain-derived.",
"   </p>",
"   <p>",
"    While damage to the affected site may occur (eg, nasal or colonic bleeding, tracheo-bronchial obstruction, hematuria), the clinical course is usually benign and surgical excision may be the only treatment needed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/15/7418/abstract/56,58,59\">",
"     56,58,59",
"    </a>",
"    ]. If there is evidence of an underlying clonal plasma cell disorder in patients with localized amyloidosis, it is important to confirm the absence of systemic AL amyloidosis with an investigation for sites of additional disease (ie, liver function tests, 24-hour urine protein, serum creatinine and echocardiography) to ensure appropriate management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of low molecular weight subunits of a variety of normal serum proteins. AL amyloidosis (previously called primary amyloidosis) is a clonal plasma cell proliferative disorder in which fibrils of monoclonal light chains are deposited in the kidney and other tissues. Affected patients may have amyloidosis alone or in association with other plasma cell dyscrasias (multiple myeloma, Waldenstrom macroglobulinemia). (See",
"      <a class=\"local\" href=\"#H143697\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation in AL amyloidosis depends on the number and nature of the organs affected. Non-specific systemic symptoms, including fatigue and unintentional weight loss, are common. Other common clinical presentations include nephrotic syndrome, restrictive cardiomyopathy, peripheral neuropathy, and hepatomegaly with elevated liver enzymes. Other less common but suggestive signs are macroglossia, purpura, and an unexplained bleeding diathesis. (See",
"      <a class=\"local\" href=\"#H1664672\">",
"       'Systemic presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AL amyloidosis requires a biopsy. An abdominal fat pad aspirate and bone marrow biopsy are the preferred sites to biopsy in patients with suspected AL amyloidosis. Either or both are positive in 90 percent of patients with AL amyloidosis. (See",
"      <a class=\"local\" href=\"#H1665772\">",
"       'Tissue biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic criteria for AL amyloidosis require the presence of",
"      <strong>",
"       all",
"      </strong>",
"      of the following (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnostic criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Presence of an amyloid-related systemic syndrome (eg, renal, liver, heart, gastrointestinal tract or peripheral nerve involvement). (See",
"      <a class=\"local\" href=\"#H1664672\">",
"       'Systemic presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Positive amyloid staining by Congo red in any tissue (eg, fat aspirate, bone marrow or organ biopsy). (See",
"      <a class=\"local\" href=\"#H1666055\">",
"       'Identifying amyloid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence that the amyloid is light chain-related established by direct examination of the amyloid (eg, using mass spectrometry based proteomic analysis; note that immunohistochemistry results to type amyloid may be unreliable). (See",
"      <a class=\"local\" href=\"#H1666063\">",
"       'Determining the type of amyloid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence of a monoclonal plasma cell proliferative disorder (eg, presence of a serum or urine M protein, abnormal serum free light chain ratio, or clonal plasma cells in the bone marrow). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H2212928#H2212928\">",
"       \"Recognition of monoclonal proteins\", section on 'Serum free light chains'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AL amyloidosis should be distinguished from other forms of amyloidosis, from localized amyloidosis, and from other types of monoclonal immunoglobulin deposition diseases (MIDD) because the clinical course and therapy are markedly different. Other forms of amyloidosis will demonstrate staining with Congo red (a characteristic of amyloid), but direct examination of the amyloid material will not reveal immunoglobulin light chains (as seen in AL amyloidosis). Other forms of MIDD will have evidence of a monoclonal plasma cell proliferative disorder and many will demonstrate light chains in the serum. However, AL amyloidosis is the only MIDD that will demonstrate staining with Congo red. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/1\">",
"      Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/2\">",
"      Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/3\">",
"      Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/4\">",
"      Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/5\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/6\">",
"      Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998; 82:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/7\">",
"      Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc 2010; 85:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/8\">",
"      Alpers CE, Cotran RS. Neoplasia and glomerular injury. Kidney Int 1986; 30:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/9\">",
"      Menke DM, Kyle RA, Fleming CR, et al. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc 1993; 68:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/10\">",
"      Eder L, Bitterman H. Image in clinical medicine. Amyloid purpura. N Engl J Med 2007; 356:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/11\">",
"      Yood RA, Skinner M, Rubinow A, et al. Bleeding manifestations in 100 patients with amyloidosis. JAMA 1983; 249:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/12\">",
"      Mumford AD, O'Donnell J, Gillmore JD, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000; 110:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/13\">",
"      Sucker C, Hetzel GR, Grabensee B, et al. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis 2006; 47:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/14\">",
"      Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstr&ouml;m's macroglobulinemia. J Clin Oncol 1993; 11:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/15\">",
"      Gertz MA, Kyle RA. Amyloidosis with IgM monoclonal gammopathies. Semin Oncol 2003; 30:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/16\">",
"      Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008; 87:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/17\">",
"      Wechalekar AD, Lachmann HJ, Goodman HJ, et al. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008; 112:4009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/18\">",
"      Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/19\">",
"      Gertz MA, Buadi FK, Hayman SR, et al. Immunoglobulin D amyloidosis: a distinct entity. Blood 2012; 119:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/20\">",
"      Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience. Am J Med 1987; 82:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/21\">",
"      Duston MA, Skinner M, Meenan RF, Cohen AS. Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum 1989; 32:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/22\">",
"      Sungur C, Sungur A, Ruacan S, et al. Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever. Kidney Int 1993; 44:834.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/24\">",
"      Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med 1980; 302:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/25\">",
"      Sch&ouml;nland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012; 119:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/26\">",
"      Novak L, Cook WJ, Herrera GA, Sanders PW. AL-amyloidosis is underdiagnosed in renal biopsies. Nephrol Dial Transplant 2004; 19:3050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/27\">",
"      Anesi E, Palladini G, Perfetti V, et al. Therapeutic advances demand accurate typing of amyloid deposits. Am J Med 2001; 111:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/28\">",
"      Herrera GA, Sanders PW, Reddy BV, et al. Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain-related renal diseases. Ultrastruct Pathol 1994; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/29\">",
"      Westermark P, Benson L, Juul J, Sletten K. Use of subcutaneous abdominal fat biopsy specimen for detailed typing of amyloid fibril protein-AL by amino acid sequence analysis. J Clin Pathol 1989; 42:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/30\">",
"      Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114:4957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/31\">",
"      Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/32\">",
"      Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011; 68:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/33\">",
"      Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012; 119:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/34\">",
"      Fonseca R, Ahmann GJ, Jalal SM, et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol 1998; 103:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/35\">",
"      Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 2001; 98:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/36\">",
"      Harrison CJ, Mazzullo H, Ross FM, et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol 2002; 117:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/37\">",
"      Bochtler T, Hegenbart U, Cremer FW, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008; 111:4700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/38\">",
"      Bryce AH, Ketterling RP, Gertz MA, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009; 94:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/39\">",
"      Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/40\">",
"      Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/41\">",
"      Paiva B, V&iacute;driales MB, P&eacute;rez JJ, et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood 2011; 117:3613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/42\">",
"      Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990; 323:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/43\">",
"      Gallo G, Wisniewski T, Choi-Miura NH, et al. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/44\">",
"      Hawkins PN, Pepys MB. Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med 1995; 22:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/45\">",
"      Jager PL, Hazenberg BP, Franssen EJ, et al. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 1998; 39:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/46\">",
"      Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/47\">",
"      Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/48\">",
"      Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/49\">",
"      Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/50\">",
"      Gertz MA, Kyle RA, Edwards WD. Recognition of congestive heart failure due to senile cardiac amyloidosis. Biomed Pharmacother 1989; 43:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/51\">",
"      Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005; 165:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/52\">",
"      Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012; 7:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/53\">",
"      Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/54\">",
"      Guidelines Working Group of UK Myeloma Forum, British Commitee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/55\">",
"      Fujita Y, Tsuji-Abe Y, Sato-Matsumura KC, et al. Nail dystrophy and blisters as sole manifestations in myeloma-associated amyloidosis. J Am Acad Dermatol 2006; 54:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/56\">",
"      Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A. Localized AL amyloidosis of the colon: an unrecognized entity. Amyloid 2003; 10:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/57\">",
"      Tirzaman O, Wahner-Roedler DL, Malek RS, et al. Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc 2000; 75:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/58\">",
"      Dom&iacute;nguez S, Wienberg P, Clar&oacute;s P, et al. Primary localized nasopharyngeal amyloidosis. A case report. Int J Pediatr Otorhinolaryngol 1996; 36:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/15/7418/abstract/59\">",
"      Zeiser R, Mikesch K, Fisch P, et al. Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. Br J Haematol 2004; 125:679.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6668 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7418=[""].join("\n");
var outline_f7_15_7418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1378183\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H143697\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Relation to other plasma cell disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H143177\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1664672\">",
"      Systemic presentations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1664740\">",
"      IgM-associated AL amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7747821\">",
"      IgD-associated AL amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664856\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1665772\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1666048\">",
"      - Choosing a biopsy site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1666055\">",
"      - Identifying amyloid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1666063\">",
"      - Determining the type of amyloid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1666444\">",
"      - Chromosomal changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1665099\">",
"      Evidence of monoclonal plasma cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666806\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1666860\">",
"      Serum amyloid P component scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58766172\">",
"      Other forms of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58766209\">",
"      - AA amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58766300\">",
"      - Hereditary (familial) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58766389\">",
"      - Senile amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58766423\">",
"      Other forms of monoclonal immunoglobulin deposition disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1662053\">",
"      - Light chain deposition disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1662108\">",
"      - Heavy chain deposition disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58766528\">",
"      Localized amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6668|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/48/2819\" title=\"picture 1\">",
"      Amyloidosis tongue enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/46/10979\" title=\"picture 2\">",
"      Periorbital amyloid purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/43/12982\" title=\"picture 3\">",
"      AL amyloidosis bruising and ecchymoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/25/33177\" title=\"picture 4\">",
"      Amyloid light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/58/22441\" title=\"picture 5\">",
"      Amyloid EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/17/38162\" title=\"picture 6\">",
"      Congo red amyloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/53/33620\" title=\"picture 7\">",
"      Amyloid goiter Congo red",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/38/16998\" title=\"picture 8\">",
"      Primary amyloid bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/22/20834\" title=\"picture 9\">",
"      LCDD tubules IF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6668|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?43/47/44787\" title=\"movie 1\">",
"      Cardiac amyloidosis parasternal long axis echocardiogram",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=related_link\">",
"      Clinical course and management of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=related_link\">",
"      Gastrointestinal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=related_link\">",
"      Genetic factors in the amyloid diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11623?source=related_link\">",
"      Musculoskeletal manifestations of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=related_link\">",
"      Pathobiology of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=related_link\">",
"      Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12470?source=related_link\">",
"      The heavy chain diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_15_7419="Indications for progestin only contraception";
var content_f7_15_7419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions in which a progestin-only contraceptive may be desirable",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Migraine headaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age over 35 years and smoker or obese",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of thromboembolic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac disease, especially coronary artery disease or heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early postpartum period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension with vascular disease or older than 35 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus with vascular disease, nephritis, or antiphospholipid antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertriglyceridemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: the American College of Obstetricians and Gynecologists. The use of hormonal contraception in women with coexisting medical conditions. ACOG practice bulletin #73, 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7419=[""].join("\n");
var outline_f7_15_7419=null;
var title_f7_15_7420="TRALI diagnostic criteria";
var content_f7_15_7420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for transfusion-related acute lung injury (TRALI) and possible TRALI",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        TRALI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible TRALI",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS)",
"        </strong>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Acute onset (during or within six hours of transfusion)",
"         </li>",
"         <li>",
"          Hypoxemia*",
"         </li>",
"         <li>",
"          Bilateral infiltrates on frontal chest radiograph",
"         </li>",
"         <li>",
"          No evidence of circulatory overload/left atrial hypertension",
"         </li>",
"         <li>",
"          No pre-existing ALI/ARDS before transfusion&nbsp;",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Same as for TRALI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         ALI/ARDS risk factor",
"         <sup>",
"          &Delta;",
"         </sup>",
"         at time of transfusion",
"        </strong>",
"       </td>",
"       <td>",
"        Must be",
"        <em>",
"         absent",
"        </em>",
"       </td>",
"       <td>",
"        Must&nbsp;be",
"        <em>",
"         present",
"        </em>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagnostic criteria for TRALI and possible TRALI share the following features: acute onset of hypoxemia, bilateral infiltrates on frontal chest radiograph, and absence of circulatory overload as the primary etiology of respiratory insufficiency. For a diagnosis of TRALI to be made, all of these features must be present. In addition, there should be no preexisting ALI/ARDS risk factors at the time of transfusion. If&nbsp;ALI/ARDS risk factors are present, the diagnostic terminology \"possible TRALI\" is appropriate.",
"    <div class=\"footnotes\">",
"     PaO2: arterial oxygen tension; FiO2: fraction of inspired oxygen; SpO2: hemoglobin oxygen saturation.",
"     <br>",
"      * Hypoxemia is defined as PaO2/FiO2 &le;300 or SpO2 &lt;90 percent on room air or other clinical evidence of hypoxemia.",
"      <br>",
"       &Delta; Risk factors for ALI/ARDS include the following: aspiration, toxic inhalation, pneumonia, toxic contusion, near drowning, shock states, severe sepsis, multiple trauma, burn injury, acute pancreatitis, cardiopulmonary bypass, or drug overdose.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44:1774.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7420=[""].join("\n");
var outline_f7_15_7420=null;
var title_f7_15_7421="Vaccination in secondary immunodeficiency";
var content_f7_15_7421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vaccinations of persons with secondary immune deficiencies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Specific immunodeficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindicated vaccines*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk-specific recommended vaccines*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effectiveness and comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)",
"       </td>",
"       <td>",
"        <p>",
"         OPV&bull;",
"        </p>",
"        <p>",
"         Smallpox",
"        </p>",
"        <p>",
"         BCG",
"        </p>",
"        <p>",
"         LAIV",
"        </p>",
"        <p>",
"         Withhold MMR and varicella in severely immunocompromised persons",
"        </p>",
"        <p>",
"         Yellow fever vaccine might have a contraindication or a precaution depending on clinical parameters of immune function",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pneumococcal ������",
"        </p>",
"        <p>",
"         Consider Hib (if not administered in infancy) and meningococcal vaccination",
"        </p>",
"       </td>",
"       <td>",
"        Measles, mumps, rubella (MMR), varicella, and all inactivated vaccines, including inactivated influenza, might be effective&Delta;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Malignant neoplasm, transplantation, immunosuppresive, or radiation therapy",
"       </td>",
"       <td>",
"        Live viral and bacterial, depending on immune status&loz;&sect;",
"       </td>",
"       <td>",
"        Pneumococcal ������",
"       </td>",
"       <td>",
"        Effectiveness of any vaccine depends on degree of immune suppression",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Asplenia",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        <p>",
"         Pneumococcal ������",
"        </p>",
"        <p>",
"         Meningococcal",
"        </p>",
"        <p>",
"         Hib (if not administered in infancy)",
"        </p>",
"       </td>",
"       <td>",
"        All routine vaccines probably effective",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Chronic renal disease",
"       </td>",
"       <td>",
"        LAIV",
"       </td>",
"       <td>",
"        <p>",
"         Pneumococcal ������",
"        </p>",
"        <p>",
"         Hepatitis B&yen;",
"        </p>",
"       </td>",
"       <td>",
"        All routine vaccines probably effective",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BCG: bacille Calmette-Guerin; Hib: haemophilus influenzae type b; LAIV: live, attenuated influenza vaccine.",
"     <br>",
"      * Other vaccines that are universally or routinely recommended should be administered if not contraindicated.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       OPV is no longer available for routine use in the United States.",
"       <br>",
"        &Delta; HIV-infected children should receive IG after exposure to measles, and can receive varicella and measles vaccine if CD4+ lymphocyte count is &gt;15 percent.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Live bacterial vaccines: BCG and Ty21a Salmonella typhi vaccine.",
"         <br>",
"          &sect; Live viral vaccines: MMR, OPV, LAIV, yellow fever, and varicella, including MMRV and HZ vaccine, and vaccinia (smallpox). Smallpox vaccine is not recommended for children or the general public.",
"          <br>",
"           &yen; Indiacted based upon the risk of dialysis-based bloodborne transmission.",
"           <br>",
"            &Dagger; In 2012, the ACIP recommended the use of the 13-valent pneumococcal conjugate vaccine in children and adults with immunocompromising conditions or functional or anatomic asplenia, in addition to the pneumococcal polysaccharide vaccine (PPSV23). Patients who have not been previously immunized with the unconjugated vaccine should receive 13-valent conjugate vaccine first, followed 8 weeks later by PPSV23. Patients who have previously received PPSV23 should receive the 13-valent conjugate vaccine after an interval of at least one year.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with permission of the American Academy of Pediatrics. Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering, LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. Copyright &copy; 2009 American Academy of Pediatrics. Udated with information from: Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7421=[""].join("\n");
var outline_f7_15_7421=null;
var title_f7_15_7422="Asthma control 0 to 4 yrs";
var content_f7_15_7422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52149%7EPULM%2F73634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52149%7EPULM%2F73634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control in children 0-4 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (children 0-4 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        1x/month",
"       </td>",
"       <td>",
"        &gt;1x/month",
"       </td>",
"       <td>",
"        &gt;1x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Risk",
"       </td>",
"       <td>",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2-3/year",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &gt;3/year",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The level of control is based on the most severe impairment or risk category. Assess impairment domain by caregiver's recall of previous 2-4 weeks. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; ICU: intensive care unit.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (children 5-11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week but not more than once on each day",
"       </td>",
"       <td>",
"        &gt;2 days/week or multiple times on &le;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;1x/month",
"       </td>",
"       <td>",
"        &ge;2x/month",
"       </td>",
"       <td>",
"        &ge;2x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Lung function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        or peak flow",
"       </td>",
"       <td class=\"sublist_other\">",
"        &gt;80 percent predicted/personal best",
"       </td>",
"       <td class=\"sublist_other\">",
"        60-80 percent predicted/personal best",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;60 percent predicted/personal best",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        /FVC",
"       </td>",
"       <td class=\"sublist_other\">",
"        &gt;80 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        75-80 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;75 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Risk",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma.",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in 1 second; FVC: forced vital capacity; ICU: intensive care unit.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7422=[""].join("\n");
var outline_f7_15_7422=null;
var title_f7_15_7423="Bronchogenic carcinoma CT II";
var content_f7_15_7423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral bronchogenic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral bronchogenic carcinoma in left upper lobe, invading the chest wall (arrow). CT shows infiltration of the left pectoralis muscle and tumor extension into the deep axillary subcutaneous fat. The findings are consistent with a T3 lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_15_7423=[""].join("\n");
var outline_f7_15_7423=null;
